

Myocarditis and Pericarditis following COVID-19 Vaccination: Rapid Systematic Review of Incidence, Risk Factors, and Clinical Course

Authors: Jennifer Pillay, MSc, Liza Bialy, MSc, Lindsay Gaudet, MSc, Aireen Wingert, MSc, Andrew S. Mackie, MD, SM, FRCPC, D. Ian Paterson, MD, FRCPC, Lisa Hartling, PhD

Appendices

Appendix 1. Search strategies

Ovid Multifile

Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations and Daily <1946 to October 05, 2021>, Embase <1974 to 2021 October 05>
Search Strategy:

-
- 1 COVID-19 Vaccines/ [COVID VACCINES PT 1] (11038)
 - 2 COVID-19/ (152175)
 - 3 SARS-CoV-2/ (101136)
 - 4 Coronavirus/ (13257)
 - 5 Betacoronavirus/ (40795)
 - 6 Coronavirus Infections/ (56640)
 - 7 (COVID-19 or COVID19).tw,kf. (324030)
 - 8 ((coronavirus* or corona virus*) and (hubei or wuhan or beijing or shanghai)).tw,kf. (10884)
 - 9 (wuhan adj5 virus*).tw,kf. (569)
 - 10 (2019-nCoV or 19nCoV or 2019nCoV).tw,kf. (3694)
 - 11 (nCoV or n-CoV or "CoV 2" or CoV2).tw,kf. (124619)
 - 12 (SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or SARS2 or SARS-2 or severe acute respiratory syndrome coronavirus 2).tw,kf. (126706)
 - 13 (2019-novel CoV or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus* or ((novel or new or nouveau) adj2 (CoV or nCoV or covid or coronavirus* or corona virus or Pandemi*2)) or (coronavirus* and pneumonia)).tw,kf. (41877)
 - 14 (novel coronavirus* or novel corona virus* or novel CoV).tw,kf. (20703)
 - 15 ((coronavirus* or corona virus*) adj2 "2019").tw,kf. (71612)
 - 16 ((coronavirus* or corona virus*) adj2 "19").tw,kf. (11500)
 - 17 ("coronavirus 2" or "corona virus 2").tw,kf. (38199)
 - 18 (OC43 or NL63 or 229E or HKU1 or HCoV* or Sars-coronavirus*).tw,kf. (8144)
 - 19 COVID-19.rx,px,ox. or severe acute respiratory syndrome coronavirus 2.os. (9120)
 - 20 (coronavirus* or corona virus*).ti. (48015)
 - 21 COVID.ti. (254131)
 - 22 ("B.1.1.7" or "B.1.351" or "B.1.617" or "B.1.427" or "B.1.429").tw,kf,rx,px,ox. (1406)
 - 23 ("P.1" and (Brazil* or variant?)).tw,kf,rx,px,ox. (3731)
 - 24 (((alpha or beta or delta or eta or gamma or iota or kappa or lambda) adj3 variant?) and (coronavirus* or corona virus* or covid*)).tw,kf. (459)
 - 25 or/2-24 [COVID-19] (397323)
 - 26 exp Vaccination/ (278048)
 - 27 ((COVID or COVID-19 or COVID19) adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kf. (15689)
 - 28 ((coronavirus* or corona virus*) adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kf. (3065)

29 ((2019-nCoV or nCoV or n-CoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or SARS2 or SARS-2 or OC43 or NL63 or 229E or HKU1 or HCoV*) adj5 (immunis* or immuniz* or inoculat* or vaccin*).tw,kf. (8201)

30 (BNT162 or BNT162-01 or BNT162a1 or BNT162b1 or BNT162b2 or BNT162c2 or N38TVC63NU).tw,kf. (1584)

31 (AZD1222 or ChAdOx1 or Covishield\$2 or B5S3K2V0G8).tw,kf. (967)

32 (mRNA-1273 or EPK39PL4R4).tw,kf. (596)

33 (mRNA adj5 (immunis* or immuniz* or inoculat* or vaccin*).tw,kf. (4901)

34 (messenger RNA adj5 (immunis* or immuniz* or inoculat* or vaccin*).tw,kf. (462)

35 LV-SMENP-DC.tw,kf. (6)

36 (Ad5-nCoV or hAdOx1 nCoV-19).tw,kf. (39)

37 ("Ad26.COVS.2" or Ad26COVS1 or JNJ 78436735 or JNJ-78436735 or JT2NS6183B).tw,kf. (195)

38 (Janssen adj5 (immunis* or immuniz* or inoculat* or vaccin*).tw,kf. (142)

39 CX-024414.tw,kf. (2)

40 (Moderna adj5 (immunis* or immuniz* or inoculat* or vaccin*).tw,kf. (470)

41 Spikevax\$2.tw,kf. (11)

42 ((Pfizer or Pfizer-BioNTech) adj5 (immunis* or immuniz* or inoculat* or vaccin*).tw,kf. (1249)

43 (Comirnaty\$2 or Tozinameran\$2).tw,kf. (202)

44 ((AstraZeneca or AZ or Oxford) adj5 (immunis* or immuniz* or inoculat* or vaccin*).tw,kf. (731)

45 Vaxzevria\$2.tw,kf. (119)

46 or/26-45 [VACCINES] (295717)

47 25 and 46 [COVID-VACCINES PT 2] (26788)

48 1 or 47 [COVID-VACCINES PTS 1-2] (28932)

49 COVID-19 Vaccines/ae [adverse events] (933)

50 Viral Vaccines/ae [adverse events] (2911)

51 Adverse Drug Reaction Reporting Systems/ (10804)

52 ((immunis* or immuniz* or inoculat* or vaccin*) adj10 (adverse* or ADE or ADEs or ADR or ADRs or complication* or harm* or safe or safety or side effect? or undesirable effect? or undesirable consequence? or undesirable outcome? or unintended effect? or unintended consequence? or unintended outcome?)).tw,kf. (76675)

53 ((post-vaccin* or post-immuni#ation* or post-innoculat* or after vaccin* or after immuni#ation* or after innoculat* or (following adj3 vaccin*) or (following adj3 immuni#ation*) or (following adj3 innoculat*)) adj10 (adverse* or ADE or ADEs or ADR or ADRs or complication* or harm* or safe or safety or side effect? or undesirable effect? or undesirable consequence? or undesirable outcome? or unintended effect? or unintended consequence? or unintended outcome?)).tw,kf. (6413)

54 ((post-vaccin* or post-immuni#ation* or post-innoculat* or after vaccin* or after immuni#ation* or after innoculat* or (following adj3 vaccin*) or (following adj3 immuni#ation*) or (following adj3 innoculat*)) adj10 (complication? or consequenc* or effect? or event? or harm* or outcome?)).tw,kf. (7716)

55 (vaccine-associated or vaccine-induced or vaccine-related).tw,kf. (20509)

56 (immuni#ation-associated or immuni#ation-induced or immuni#ation-related).tw,kf. (1855)

57 ((data or vaccin*) adj3 (monitor* or surveillance*).tw,kf. (73396)

58 Pharmacovigilance/ (5248)

59 (pharmacovigilan* or pharmaco-vigilan*).tw,kf. (18894)

60 (Canada Vigilance or Eudravigilance* or FAERS or VAERS).tw,kf. (2780)

61 Product Surveillance, Postmarketing/ (19287)

62 ((postmarket* or post-market*) adj3 surveillance*).tw,kf. (9589)

63 "Clinical Trial, Phase IV".pt. (2193)

64 ((Phase 4 or Phase IV) adj3 (evaluation? or study or studies or trial?)).tw,kf. (4910)

65 Cardiomyopathies/ (54974)

66 (cardiomyopath* or cardio-myopath* or myocardiopath* or myo-cardiopath*).tw,kf. (209222)

67 Myocarditis/ (42633)
68 myocarditis.tw,kf. (41845)
69 ((myocard* or myo-card) adj3 inflam*).tw,kf. (10214)
70 carditis.tw,kf. (4148)
71 exp Pericarditis/ (31618)
72 pericarditis.tw,kf. (27519)
73 ((pericard* or peri-card*) adj3 inflam*).tw,kf. (1118)
74 epicarditis.tw,kf. (249)
75 ((epicard* or epi-card*) adj3 inflam*).tw,kf. (260)
76 (myopericarditis or myo-pericarditis).tw,kf. (1763)
77 ((myopericard* or myo-pericard*) adj inflam*).tw,kf. (13)
78 (pleuropericarditis or pleuro-pericarditis).tw,kf. (412)
79 ((pleuropericard* or pleuropericard*) adj3 inflam*).tw,kf. (12)
80 or/49-79 [AEs, MYOCARDITIS, PERICARDITIS] (535683)
81 48 and 80 [COVID-VACCINES - AEs, MYOCARDITIS, PERICARDITIS] (6406)
82 exp Animals/ not Humans/ (16924647)
83 81 not 82 [ANIMAL-ONLY REMOVED] (4653)
84 (comment or editorial or news or newspaper article or (letter not (letter and randomized controlled trial))).pt. (4104337)
85 83 not 84 [OPINION PIECES REMOVED] (4141)
86 limit 85 to yr="2020-current" (4046)
87 (202010* or 202011* or 202012* or 2021*).dt. (1600708)
88 86 and 87 [RECORDS SINCE 1 OCT 2020] (2589)
89 88 use ppez[MEDLINE RECORDS] (2589)
90 SARS-CoV-2 vaccine/ [COVID VACCINES - PT 1] (11038)
91 coronavirus disease 2019/ (261337)
92 severe acute respiratory syndrome coronavirus 2/ (130655)
93 Coronavirinae/ (5218)
94 Betacoronavirus/ (40795)
95 coronavirus infection/ (57662)
96 (COVID-19 or COVID19).tw,kw,kf. (324030)
97 ((coronavirus* or corona virus*) and (hubei or wuhan or beijing or shanghai)).tw,kw,kf. (10884)
98 (wuhan adj5 virus*).tw,kw,kf. (584)
99 (2019-nCoV or 19nCoV or 2019nCoV).tw,kw,kf. (3694)
100 (nCoV or n-CoV or "CoV 2" or CoV2).tw,kw,kf. (124619)
101 (SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or SARS2 or SARS-2 or severe acute respiratory syndrome coronavirus 2).tw,kw,kf. (126706)
102 (2019-novel CoV or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus* or ((novel or new or nouveau) adj2 (CoV or nCoV or covid or coronavirus* or corona virus or Pandemi*2)) or (coronavirus* and pneumonia)).tw,kw,kf. (41884)
103 (novel coronavirus* or novel corona virus* or novel CoV).tw,kw,kf. (20703)
104 ((coronavirus* or corona virus*) adj2 "2019").tw,kw,kf. (71614)
105 ((coronavirus* or corona virus*) adj2 "19").tw,kw,kf. (11502)
106 ("coronavirus 2" or "corona virus 2").tw,kw,kf. (38199)
107 (OC43 or NL63 or 229E or HKU1 or HCoV* or Sars-coronavirus*).tw,kw,kf. (8144)
108 (coronavirus* or corona virus*).ti. (48015)
109 COVID.ti. (254131)
110 ("B.1.1.7" or "B.1.351" or "B.1.617" or "B.1.427" or "B.1.429").tw,kw,kf. (1406)
111 ("P.1" and (Brazil* or variant?)).tw,kw,kf. (3704)
112 (((alpha or beta or delta or eta or gamma or iota or kappa or lambda) adj3 variant?) and (coronavirus* or corona virus* or covid*)).tw,kw,kf. (461)

113 or/91-112 [COVID-19] (404957)
114 vaccination/ (246289)
115 ((COVID or COVID-19 or COVID19) adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kw,kf. (17544)
116 ((coronavirus* or corona virus*) adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kw,kf. (3913)
117 ((2019-nCoV or nCoV or n-CoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or SARS2 or SARS-2 or OC43 or NL63 or 229E or HKU1 or HCoV*) adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kw,kf. (9069)
118 (BNT162 or BNT162-01 or BNT162a1 or BNT162b1 or BNT162b2 or BNT162c2 or N38TVC63NU).tw,kw,kf. (1584)
119 (AZD1222 or ChAdOx1 or Covishield\$2 or B5S3K2V0G8).tw,kw,kf. (967)
120 (mRNA-1273 or EPK39PL4R4).tw,kw,kf. (596)
121 (mRNA adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kw,kf. (4944)
122 (messenger RNA adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kw,kf. (475)
123 LV-SMENP-DC.tw,kw,kf. (6)
124 (Ad5-nCoV or hAdOx1 nCoV-19).tw,kw,kf. (39)
125 ("Ad26.COV2.S" or Ad26COVS1 or JNJ 78436735 or JNJ-78436735 or JT2NS6183B).tw,kw,kf. (195)
126 (Janssen adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kf. (142)
127 CX-024414.tw,kw,kf. (2)
128 (Moderna adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kw,kf. (483)
129 Spikevax\$2.tw,kw,kf. (11)
130 ((Pfizer or Pfizer-BioNTech) adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kf,kw. (1264)
131 (Comirnaty\$2 or Tozinameran\$2).tw,kw,kf. (202)
132 ((AstraZeneca or AZ or Oxford) adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kw,kf. (733)
133 Vaxzevria\$2.tw,kw,kf. (119)
134 or/114-133 [VACCINES] (265426)
135 113 and 134 [COVID VACCINES - PT 2] (27369)
136 90 or 135 [COVID VACCINES - PTS 1 & 2] (29374)
137 virus vaccine/ae [adverse drug event] (999)
138 exp severe acute respiratory syndrome vaccine/ae [adverse drug event] (470)
139 ((immunis* or immuniz* or inoculat* or vaccin*) adj10 (adverse* or ADE or ADEs or ADR or ADRs or complication* or harm* or safe or safety or side effect? or undesirable effect? or undesirable consequence? or undesirable outcome? or unintended effect? or unintended consequence? or unintended outcome?)).tw,kw,kf. (76966)
140 ((post-vaccin* or post-immuni#ation* or post-innoculat* or after vaccin* or after immuni#ation* or after innoculat* or (following adj3 vaccin*) or (following adj3 immuni#ation*) or (following adj3 innoculat*)) adj10 (adverse* or ADE or ADEs or ADR or ADRs or complication* or harm* or safe or safety or side effect? or undesirable effect? or undesirable consequence? or undesirable outcome? or unintended effect? or unintended consequence? or unintended outcome?)).tw,kw,kf. (6417)
141 ((post-vaccin* or post-immuni#ation* or post-innoculat* or after vaccin* or after immuni#ation* or after innoculat* or (following adj3 vaccin*) or (following adj3 immuni#ation*) or (following adj3 innoculat*)) adj10 (complication? or consequenc* or effect? or event? or harm* or outcome?)).tw,kw,kf. (7718)
142 (vaccine-associated or vaccine-induced or vaccine-related).tw,kw,kf. (20509)
143 (immuni#ation-associated or immuni#ation-induced or immuni#ation-related).tw,kw,kf. (1855)
144 exp pharmacovigilance/ (5254)
145 (pharmacovigilan* or pharmaco-vigilan*).tw,kw,kf. (18894)
146 (Canada Vigilance or Eudravigilance* or FAERS or VAERS).tw,kw,kf. (2780)

147 exp postmarketing surveillance/ (37209)
148 ((postmarket* or post-market*) adj3 surveillance*).tw,kw,kf. (9603)
149 phase 4 clinical trial/ (4491)
150 ((Phase 4 or Phase IV) adj3 (evaluation? or study or studies or trial?)).tw,kw,kf. (4910)
151 cardiomyopathy/ (90014)
152 (cardiomyopath* or cardio-myopath* or myocardiopath* or myo-cardiopath*).tw,kw,kf. (209222)
153 exp myocarditis/ (45666)
154 myocarditis.tw,kw,kf. (41845)
155 ((myocard* or myo-card) adj3 inflam*).tw,kw,kf. (12899)
156 carditis.tw,kw,kf. (4148)
157 exp pericarditis/ (31618)
158 pericarditis.tw,kw,kf. (27519)
159 ((pericard* or peri-card*) adj3 inflam*).tw,kw,kf. (1222)
160 epicarditis.tw,kw,kf. (249)
161 ((epicard* or epi-card*) adj3 inflam*).tw,kw,kf. (391)
162 (myopericarditis or myo-pericarditis).tw,kw,kf. (1763)
163 ((myopericard* or myo-pericard*) adj inflam*).tw,kw,kf. (25)
164 (pleuropericarditis or pleuro-pericarditis).tw,kw,kf. (412)
165 ((pleuropericard* or pleuropericard*) adj3 inflam*).tw,kw,kf. (13)
166 or/137-165 [MYOCARDITIS, PERICARDITIS] (483566)
167 136 and 166 [COVID-VACCINES - MYOCARDITIS, PERICARDITIS] (6014)
168 exp animal/ or exp animal experimentation/ or exp animal model/ or exp animal experiment/ or
nonhuman/ or exp vertebrate/ (54214081)
169 exp human/ or exp human experimentation/ or exp human experiment/ (42550990)
170 168 not 169 (11664830)
171 167 not 170 [ANIMAL-ONLY REMOVED] (5784)
172 editorial.pt. (1287357)
173 letter.pt. not (letter.pt. and randomized controlled trial/) (2336030)
174 171 not (172 or 173) [OPINION PIECES REMOVED] (5259)
175 limit 174 to yr="2020-current" (5170)
176 (202010* or 202011* or 202012* or 2021*).dc. (2457999)
177 175 and 176 [RECORDS PUBLISHED/ADDED SINCE OCT 2020] (2500)
178 177 use oemzd [EMBASE RECORDS] (2500)
179 89 or 178 [BOTH DATABASES] (5089)
180 remove duplicates from 179 (3235)[TOTAL UNIQUE RECORDS]
181 180 use ppez [MEDLINE UNIQUE RECORDS] (2530)
182 180 use oemzd [EMBASE UNIQUE RECORDS] (705)

Cochrane Library

-	+	#1	[mh "COVID-19 Vaccines"]	Limits	55
-	+	#2	[mh "COVID-19"]	Limits	657
-	+	#3	[mh "SARS-CoV-2"]	Limits	479
-	+	#4	[mh *Coronavirus]	Limits	4
-	+	#5	[mh *Betacoronavirus]	Limits	127
-	+	#6	[mh *Coronavirus Infections]	Limits	657
-	+	#7	("COVID-19" or COVID19):ti,ab,kw	Limits	7299
-	+	#8	((coronavirus* or corona virus*) and (hubei or wuhan or beijing or shanghai)):ti,ab,kw	Limits	219
-	+	#9	(wuhan NEAR/5 virus):ti,ab,kw	Limits	9
-	+	#10	("2019-nCoV" or 19nCoV or 2019nCoV):ti,ab,kw	Limits	10
-	+	#11	(nCoV or n-CoV or "CoV 2" or CoV2):ti,ab,kw	Limits	690
-	+	#12	("SARS-CoV-2" or "SARS-CoV2" or "SARSCoV-2" or SARSCoV2 or SARS2 or "SARS-2" or "severe acute respiratory syndrome coronavirus 2"):ti,ab,kw	Limits	3039
-	+	#13	("2019-novel CoV" or "Sars-coronavirus2" or "Sars-coronavirus-2" or "SARS-like coronavirus" or "SARS-like coronaviruses" or ((novel or new or <u>novel</u>) NEAR/2 (CoV or nCoV or covid or coronavirus* or "corona virus" or <u>Pandemi</u> 2)) or (coronavirus* and pneumonia):ti,ab,kw	Limits	1367
-	+	#14	("novel coronavirus" or "novel coronaviruses" or "novel corona virus" or "novel corona viruses" or "novel CoV"):ti,ab,kw	Limits	478
-	+	#15	((coronavirus* or "corona virus" or "corona viruses") NEAR/2 "2019"):ti,ab,kw	Limits	2503
-	+	#16	((coronavirus* or "corona virus" or "corona viruses") NEAR/2 "19"):ti,ab,kw	Limits	299
-	+	#17	("coronavirus 2" or "corona virus 2"):ti,ab,kw	Limits	765
-	+	#18	(OC43 or NL63 or 229E or HKU1 or HCoV* or (Sars NEXT coronavirus)):ti,ab,kw	Limits	84
-	+	#19	(coronavirus* or "corona virus" or "corona viruses"):ti	Limits	736
-	+	#20	COVID:ti	Limits	5641

-	+	#21	("B.1.1.7" or "B.1.351" or "B.1.617" or "B.1.427" or "B.1.429");ti,ab,kw	Limits	16
-	+	#22	("P.1" and (Brazil" or variant"));ti,ab,kw	Limits	175
-	+	#23	((alpha or beta or delta or eta or gamma or iota or kappa or lambda) NEAR/3 variant*) and (coronavirus* or corona virus* or covid*);ti,ab,kw	Limits	7
-	+	#24	{or #2-#23}	Limits	7898
-	+	#25	[mh Vaccination]	Limits	2680
-	+	#26	((COVID or "COVID-19" or COVID19) NEAR/5 (immunis* or immuniz* or inoculat* or vaccin*));ti,ab,kw	Limits	493
-	+	#27	((coronavirus* or "corona virus" or "corona viruses") NEAR/5 (immunis* or immuniz* or inoculat* or vaccin*));ti,ab,kw	Limits	100
-	+	#28	((("2019-nCoV" or nCoV or nCoV or "SARS-CoV-2" or "SARS-CoV2" or "SARSCoV-2" or SARSCoV2 or SARS2 or "SARS-2" or OC43 or NL63 or 229E or HKU1 or hCoV) NEAR/5 (immunis* or immuniz* or inoculat* or vaccin*));ti,ab,kw	Limits	221
-	+	#29	(BNT162 or "BNT162-01" or BNT162a1 or BNT162b1 or BNT162b2 or BNT162c2 or N38TVC63NU);ti,ab,kw	Limits	38
-	+	#30	(AZD1222 or ChAdOx1 or Covshield* or B5S3K2V0G8);ti,ab,kw	Limits	63
-	+	#31	("mRNA-1273" or EPK39PL4R4);ti,ab,kw	Limits	24
-	+	#32	(mRNA NEAR/5 (immunis* or immuniz* or inoculat* or vaccin*));ti,ab,kw	Limits	100
-	+	#33	("messenger RNA" NEAR/5 (immunis* or immuniz* or inoculat* or vaccin*));ti,ab,kw	Limits	24
-	+	#34	"LV-SMENP-DC";ti,ab,kw	Limits	0
-	+	#35	("Ad5-nCoV" or "hAdOx1 nCoV-19");ti,ab,kw	Limits	0
-	+	#36	("Ad26.COV2.S" or Ad26COVS1 or "JNJ 78436735" or "JNJ-78436735" or JT2NS6183B);ti,ab,kw	Limits	22
-	+	#37	(Janssen NEAR/5 (immunis* or immuniz* or inoculat* or vaccin*));ti,ab,kw	Limits	18
-	+	#38	"CX-024414";ti,ab,kw	Limits	2
-	+	#39	(Moderna NEAR/5 (immunis* or immuniz* or inoculat* or vaccin*));ti,ab,kw	Limits	20
-	+	#40	Spikevax*;ti,ab,kw	Limits	0
-	+	#41	((Pfizer or "Pfizer-BioNTech") NEAR/5 (immunis* or immuniz* or inoculat* or vaccin*));ti,ab,kw	Limits	47
-	+	#42	(Comirnaty* or Tozinameran*);ti,ab,kw	Limits	10
-	+	#43	((AstraZeneca or AZ or Oxford) NEAR/5 (immunis* or immuniz* or inoculat* or vaccin*));ti,ab,kw	Limits	34
-	+	#44	Vaxzevina*;ti,ab,kw	Limits	6
-	+	#45	{or #25-#44}	Limits	3419
-	+	#46	#24 AND #45	Limits	638
-	+	#47	#1 OR #46	Limits	638
-	+	#48	[mh "COVID-19 Vaccines"/AE]	Limits	30
-	+	#49	[mh "Viral Vaccines"/AE]	Limits	221
-	+	#50	[mh "Adverse Drug Reaction Reporting Systems"]	Limits	90
-	+	#51	((immunis* or immuniz* or inoculat* or vaccin*) NEAR/10 (adverse* or ADE or ADEs or ADR or ADRs or complication* or harm* or safe or safety or "side effect" or "side effects" or "undesirable effect" or "undesirable effects" or "undesirable consequence" or "undesirable consequences" or "undesirable outcome" or "undesirable outcomes" or "unintended effect" or "unintended effects" or "unintended consequence" or "unintended consequences" or "unintended outcome" or "unintended outcome's"));ti,ab,kw	Limits	12385
-	+	#52	((post NEXT vaccin*) or (post NEXT immunisation*) or (post NEXT immunization*) or (post NEXT inoculat*) or (after NEXT vaccin*) or (after NEXT immunisation*) or (after NEXT immunization*) or (after NEXT inoculat*) or (following NEAR/3 vaccin*) or (following NEAR/3 immunisation*) or (following NEAR/3 immunization*) or (following NEAR/3 inoculat*)) NEAR/10 (adverse* or ADE or ADEs or ADR or ADRs or complication* or harm* or safe or safety or "side effect" or "side effects" or "undesirable effect" or "undesirable effects" or "undesirable consequence" or "undesirable consequences" or "undesirable outcome" or "undesirable outcomes" or "unintended effect" or "unintended effects" or "unintended consequence" or "unintended consequences" or "unintended outcome" or "unintended outcome's"));ti,ab,kw	Limits	1493
-	+	#53	((post NEXT vaccin*) or (post NEXT immunisation*) or (post NEXT immunization*) or (post NEXT inoculat*) or (after NEXT vaccin*) or (after NEXT immunisation*) or (after NEXT immunization*) or (after NEXT inoculat*) or (following NEAR/3 vaccin*) or (following NEAR/3 immunisation*) or (following NEAR/3 immunization*) or (following NEAR/3 inoculat*)) NEAR/10 (complication* or consequenc* or effect or effects or event or events or harm* or outcome*);ti,ab,kw	Limits	1214
-	+	#54	("vaccine-associated" or "vaccine-induced" or "vaccine-related");ti,ab,kw	Limits	1451
-	+	#55	("immunisation-associated" or "immunisation-induced" or "immunisation-related" or "immunization-associated" or "immunization-induced" or "immunization-related");ti,ab,kw	Limits	38
-	+	#56	((data or vaccin*) NEAR/3 (monitor* or surveillance*));ti,ab,kw	Limits	4798
-	+	#57	[mh Pharmacovigilance]	Limits	18

-	+	#58	(pharmacovigilant * or (pharmaco NEXT vigilant ")):ti,ab,kw	Limits	318
-	+	#59	("Canada Vigilance" or Eudravigilance * or FAERS or VAERS):ti,ab,kw	Limits	19
-	+	#60	[mh " Product Surveillance , Postmarketing "]	Limits	100
-	+	#61	((postmarket * or (post NEXT market*)) NEAR/3 surveillance):ti,ab,kw	Limits	732
-	+	#62	"Clinical Trial, Phase IV":pt	Limits	1201
-	+	#63	((("Phase 4" or "Phase IV") NEAR/3 (evaluation* or study or studies or trial or trials)):ti,ab,kw	Limits	2770
-	+	#64	[mh " Cardiomyopathies "]	Limits	677
-	+	#65	(cardiomyopath * or (cardio NEXT myopath *) or myocardiopath * or (myo NEXT cardiopath ")):ti,ab,kw	Limits	4440
-	+	#66	[mh Myocarditis]	Limits	93
-	+	#67	myocarditis :ti,ab,kw	Limits	1208
-	+	#68	((myocard * or (myo NEXT card*)) NEAR/3 inflam):ti,ab,kw	Limits	268
-	+	#69	carditis :ti,ab,kw	Limits	36
-	+	#70	[mh Pericarditis]	Limits	63
-	+	#71	pericarditis :ti,ab,kw	Limits	349
-	+	#72	((pericard * or (peri NEXT card*)) NEAR/3 inflam):ti,ab,kw	Limits	22
-	+	#73	epicarditis :ti,ab,kw	Limits	2
-	+	#74	((epicard * or (epi NEXT card*)) NEAR/3 inflam):ti,ab,kw	Limits	5
-	+	#75	(myopericarditis or " myo-pericarditis "):ti,ab,kw	Limits	12
-	+	#76	((myopericard * or (myo NEXT pericard *)) NEAR/3 inflam):ti,ab,kw	Limits	1
-	+	#77	(pleuropericarditis or " pleuro-pericarditis "):ti,ab,kw	Limits	3
-	+	#78	((pleuropericard * or (pleuro NEXT pericard *)) NEAR/3 inflam):ti,ab,kw	Limits	0
-	+	#79	[or #48-#78]	Limits	27721
-	+	#80	#47 AND #79	Limits	339


with Cochrane Library publication date from Oct 2020 to Oct 2021

6-Oct-21

Original Deduped

MEDLINE	2530	2511
Embase	705	675
CDSR	2	0
CENTRAL	337	253
TOTAL	3574	3439

Appendix 2. Literature flow



Appendix 3. Supplements to Tables 2 and 3

Descriptions of surveillance systems used in studies within this report

CAEFISS: Managed by PHAC, monitors the safety of marketed vaccines in Canada through both passive and active reporting strategies. Reports are submitted by public health authorities in provinces and territories, who in turn receive them from local public health units. Provincial and territorial authorities also receive reports from federal authorities that provide immunization in their jurisdictions. Active surveillance is also carried out by 12 pediatric centres across Canada, which screen all hospital admissions for potential vaccine-related adverse events.

CVP: Passive surveillance program that collects reports of suspected adverse reactions to health products. Reports are submitted by health professionals and consumers on a voluntary basis either directly to Health Canada or to the market authorization holder, who in turn is required to submit reports of adverse events to Health Canada through the Canada Vigilance Program.

EudraVigilance: Passive surveillance system for the European Economic Area. Healthcare providers and patients can report any adverse effects from medical products, including vaccines. Patients, consumers and healthcare professionals report suspected side effects to either the national medicines regulatory authority or the pharmaceutical company that holds the marketing authorisation for the medicine. These reports are then transmitted electronically to EudraVigilance.

VAERS: Passive surveillance system for the United States, to which healthcare providers and patients can report adverse events from medical products, including vaccines. Providers are required to report to VAERS adverse events (including administration errors, serious adverse events, cases of multisystem inflammatory syndrome, and cases of COVID-19 that result in hospitalization or death) that occur after receipt of any COVID-19 vaccine.

Yellow Card: The Yellow Card scheme in the United Kingdom is a passive surveillance system to which anybody can voluntarily report any suspected adverse reactions or side effects to the vaccine. The reports are continually reviewed to detect possible new side effects that may require regulatory action, and to differentiate these from things that would have happened regardless of the vaccine or medicine being administered, for instance due to underlying or undiagnosed illness.

References for included studies in question 1 labeled based on data sources

Study	Reference(s)
Active Surveillance	
Clalit Health May 24a	Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med. 2021. doi: https://dx.doi.org/10.1056/NEJMoa2110737 .
Clalit Health May 24b	Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2021;385(12):1078-1090. doi: https://dx.doi.org/10.1056/NEJMoa2110475 .
Genesis Healthcare Jan 3	Bardenheier BH, Gravenstein S, Blackman C, et al. Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents. Vaccine. 2021;39(29):3844-3851. doi: https://dx.doi.org/10.1016/j.vaccine.2021.05.088 .
Genesis Healthcare Feb 14	Bardenheier BH, Gravenstein S, Blackman C, et al. Adverse Events Following One Dose of mRNA COVID-19 Vaccination Among US Nursing Home Residents With and Without a Previous SARS-CoV-2 Infection. J Am Med Dir Assoc. 2021;28:28. doi: https://dx.doi.org/10.1016/j.jamda.2021.08.024 .

Study	Reference(s)
Israel MOH May 31	Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med. 2021. doi: https://dx.doi.org/10.1056/NEJMoa2109730 .
Israeli Defense Forces May 7	Levin D, Shimon G, Fadlon-Deraï M, et al. Myocarditis following COVID-19 vaccination - A case series. Vaccine. 2021;39(42):6195-6200. doi: https://dx.doi.org/10.1016/j.vaccine.2021.09.004 .
KPSC Jul 20	Simone A, Herald J, Chen A, et al. Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. JAMA Intern Med. 2021;04:04. doi: https://dx.doi.org/10.1001/jamainternmed.2021.5511 .
Providence Health May 25	Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and Pericarditis After Vaccination for COVID-19. Jama. 2021;326(12):1210-1212. doi: https://dx.doi.org/10.1001/jama.2021.13443 .
US Military Apr 30	Montgomery J, Ryan M, Engler R, et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol. 2021;29:29. doi: https://dx.doi.org/10.1001/jamacardio.2021.2833 .
VSD Jun 26	Klein NP, Lewis N, Goddard K, et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. Jama. 2021;03:03. doi: https://dx.doi.org/10.1001/jama.2021.15072 .
VSD Aug 21	Klein NP. Rapid Cycle Analysis to Monitor the Safety of COVID-19 Vaccines in Near Real-Time within the Vaccine Safety Datalink: Myocarditis and Anaphylaxis. Aug 30 Advisory Committee on Immunization Practices (ACIP) https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-08-30/04-COVID-Klein-508.pdf
VSD Oct 6	Klein NP. Myocarditis Analysis in the Vaccine Safety Datalink: Rapid Cycle Analyses and "Head-to-Head" Product Comparisons. 21 October 2021 2021. Advisory Committee on Immunization Practices (ACIP). Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/08-COVID-Klein-508.pdf .
Passive Surveillance	
CAEFISS & CVP	Public Health Agency of Canada. Canadian COVID-19 vaccination safety report. Ottawa: Public Health Agency of Canada; October 18, 2021 2021. Available from: https://health-infobase.canada.ca/covid-19/vaccine-safety/#a4 .
EudraVigilance Oct 19	European Medicines Agency. EudraVigilance - European database of suspected adverse drug reaction reports. European Medicines Agency. Available from: https://www.adrreports.eu/en/eudravigilance.html . Published 2021. Accessed October 26, 2021, 2021.
Israel MOH May 30	Israel Ministry of Health. Surveillance of Myocarditis (Inflammation of the Heart Muscle) Cases Between December 2020 and May 2021 (Including). Available from: https://www.gov.il/en/departments/news/01062021-03 . Published 2021. Updated June 2, 2021. Accessed.

Study	Reference(s)
VAERS Jun 11	Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(27):977-982. doi: https://dx.doi.org/10.15585/mmwr.mm7027e2 .
VAERS Jun 18a	Høeg TB, Krug A, Stevenson J, Mandrola J. SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis. 2021. doi: https://dx.doi.org/10.1101/2021.08.30.21262866 .
VAERS Jun 18b	Lazaros G, Anastassopoulou C, Hatziantoniou S, et al. A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States. Vaccine. 2021. doi: https://dx.doi.org/10.1016/j.vaccine.2021.09.078 .
VAERS Jun 30	Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. MMWR Morb Mortal Wkly Rep. 2021;70(32):1094-1099. doi: https://dx.doi.org/10.15585/mmwr.mm7032e4 .
VAERS Aug 6	Lane S, Shakir S. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccines: A review of spontaneously reported data from the UK, Europe, and the U. 2021. doi: https://dx.doi.org/10.1101/2021.09.09.21263342 .
VAERS Oct 6	Su JR. Myopericarditis following COVID-19 vaccination: Updates from the Vaccine Adverse Event Reporting System (VAERS). CDC October 21, 2021 2021. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/07-COVID-Su-508.pdf .
Yellow Card Oct 13	Medicine & Healthcare products Regulatory Agency. Coronavirus vaccine - weekly summary of Yellow Card reporting. Government of the United Kingdom. Available from: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting . Published 2021. Updated October 21, 2021. Accessed October 21, 2021, 2021.
Randomized Controlled Trials	
AZD1222 Trial, Phase 3 (AstraZeneca)	Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. 2021;29:29. doi: https://dx.doi.org/10.1056/NEJMoa2105290 .
AZD1222 Trial, Pooled Analysis (AstraZeneca)	Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. doi: https://dx.doi.org/10.1016/S0140-6736(20)32661-1 .
	Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881-891. doi: https://dx.doi.org/10.1016/S0140-6736(21)00432-3 .

Study	Reference(s)
C4591001 Trial, Adolescent cohort (Pfizer)	Frenck RW, Jr., Klein NP, Kitchin N, et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021;385(3):239-250. doi: https://dx.doi.org/10.1056/NEJMoa2107456 .
C4591001 Trial, Adult cohort (Pfizer)	Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. doi: https://dx.doi.org/10.1056/NEJMoa2034577 . Thomas SJ, Moreira ED, Jr., Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021; 15:15. doi: https://dx.doi.org/10.1056/NEJMoa2110345 .
COVE trial (Moderna)	Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-416. doi: https://dx.doi.org/10.1056/NEJMoa2035389 . El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021. doi: https://dx.doi.org/10.1056/NEJMoa2113017 .
Teen COVE trial (Moderna)	Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. N Engl J Med. 2021;11:11. doi: https://dx.doi.org/10.1056/NEJMoa2109522 .
ENSEMBLE Trial (Janssen)	Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-2201. doi: https://dx.doi.org/10.1056/NEJMoa2101544 .

Appendix 4: Study Characteristics Tables and Risk of Bias Tables

Table A1. Study characteristics of observational studies using data from active surveillance systems (question 1)

Dataset Dates Country	Vaccines Studied	Sample Size; Demographics; Previous Covid-19 diagnoses	Study Group(s)	Outcome(s); Risk Interval; Case Ascertainment	Analysis	Results																																										
VSD† Oct 9 Dec 14 2020 to Oct 9 USA (Klein, 2021a)	Pfizer- BioNTech (60% of dose 2) or Moderna	Total doses 14,214,955 (71.5% eligible people fully vaccinated) to 7.5 million people NR Excluded from analysis if COVID-19 diagnosis ≤30 d before vaccination	1. Vaccinated in previous 0-21 d 2. Concurrent previous vaccinees (22 to 42 d previously for similar individuals after vaccine dose 1 or 2 [most dose 2]) Interval between doses: majority 21 d (Pfizer) and 28 d Moderna)	Myocarditis/pericarditis/ myopericarditis (combined & separate for head-to- head comparison) ICD-10 using inclusion and exclusionary codes via clinical expert consultation; cases among 12-39 y confirmed by medical record review ED and in-patient records used Blinding to vaccine status NR Risk interval: 0-21 d & 0-7 d	Weekly, rapid cycle analysis Adjusted incident rate ratio (aIRR) estimated by Poisson regression adjusted for age, sex, race and ethnicity, health plan, and calendar day; 1-sided P < .0048 for statistical signal Excess risk/incidence per million doses (IR – [IR/IRR]) <u>Exploratory analyses</u> (no prespecified level of significance): by dose and vaccine type; for 12- 39 y by dose, vaccine type and with shorter risk intervals; head-to-head Moderna vs Pfizer in 18- 39 y (also excluded pericarditis)	Events: 138 (not confirmed) after either dose Incidence: 138/14,214,955 = 9.7 per million doses aIRR: 1.72 p <.001 (statistical signal) <u>Exploratory analyses:</u> 12-39 y (all confirmed cases) Group 1: 74 cases in 0-21 d interval (59 [80%] after dose 2; 39 [53% in 0-7 d]); 44 (59%) in 18-39 y and 30 (40.5% in 12-17 y Clustering at 0-5 d after vaccine (p<.0001) 0-7 d risk interval <table border="1"> <thead> <tr> <th></th> <th>aIRR (95% CI)</th> <th>Excess risk per million doses</th> </tr> </thead> <tbody> <tr> <td>Both doses</td> <td>21.73 (9.53 to 57.34)</td> <td>11.8</td> </tr> <tr> <td>Dose 2</td> <td>31.28 (12.83 to 91.40)</td> <td>21.1</td> </tr> <tr> <td>Pfizer (<u>12-39y</u>)</td> <td>19.31 (7.66 to 57.79)</td> <td>11.5</td> </tr> <tr> <td>Dose 2</td> <td>30.27 (11.01 to 104.4)</td> <td>21.5</td> </tr> <tr> <td>Moderna (<u>18-39y</u>)</td> <td>37.51 (6.69 to 803.00)</td> <td>12.8</td> </tr> <tr> <td>Dose 2</td> <td>NE (11.75 to NE)</td> <td>21.0</td> </tr> </tbody> </table> (For dose 1: aIRR range 8.7-10.5, all significant; excess cases 2.3- 5.2) 0-7 d risk interval (18-39 y only) <table border="1"> <thead> <tr> <th></th> <th>aIRR (95% CI)</th> <th>Excess risk per million doses</th> </tr> </thead> <tbody> <tr> <td>Both doses</td> <td>12.61 (5.27 to 34.47)</td> <td>8.4</td> </tr> <tr> <td>Dose 2</td> <td>14.33 (5.50 to 43.88)</td> <td>13.1</td> </tr> <tr> <td>Pfizer</td> <td>7.98 (2.72 to 26.50)</td> <td>5.7</td> </tr> <tr> <td>Dose 2</td> <td>8.77 (2.56 to 35.34)</td> <td>8.5</td> </tr> <tr> <td>Moderna</td> <td>37.42 (6.68 to 801.33)</td> <td>12.8</td> </tr> <tr> <td>Dose 2</td> <td>NE (11.70 – NE)</td> <td>21.0</td> </tr> </tbody> </table>		aIRR (95% CI)	Excess risk per million doses	Both doses	21.73 (9.53 to 57.34)	11.8	Dose 2	31.28 (12.83 to 91.40)	21.1	Pfizer (<u>12-39y</u>)	19.31 (7.66 to 57.79)	11.5	Dose 2	30.27 (11.01 to 104.4)	21.5	Moderna (<u>18-39y</u>)	37.51 (6.69 to 803.00)	12.8	Dose 2	NE (11.75 to NE)	21.0		aIRR (95% CI)	Excess risk per million doses	Both doses	12.61 (5.27 to 34.47)	8.4	Dose 2	14.33 (5.50 to 43.88)	13.1	Pfizer	7.98 (2.72 to 26.50)	5.7	Dose 2	8.77 (2.56 to 35.34)	8.5	Moderna	37.42 (6.68 to 801.33)	12.8	Dose 2	NE (11.70 – NE)	21.0
	aIRR (95% CI)	Excess risk per million doses																																														
Both doses	21.73 (9.53 to 57.34)	11.8																																														
Dose 2	31.28 (12.83 to 91.40)	21.1																																														
Pfizer (<u>12-39y</u>)	19.31 (7.66 to 57.79)	11.5																																														
Dose 2	30.27 (11.01 to 104.4)	21.5																																														
Moderna (<u>18-39y</u>)	37.51 (6.69 to 803.00)	12.8																																														
Dose 2	NE (11.75 to NE)	21.0																																														
	aIRR (95% CI)	Excess risk per million doses																																														
Both doses	12.61 (5.27 to 34.47)	8.4																																														
Dose 2	14.33 (5.50 to 43.88)	13.1																																														
Pfizer	7.98 (2.72 to 26.50)	5.7																																														
Dose 2	8.77 (2.56 to 35.34)	8.5																																														
Moderna	37.42 (6.68 to 801.33)	12.8																																														
Dose 2	NE (11.70 – NE)	21.0																																														

Dataset Dates Country	Vaccines Studied	Sample Size; Demographics; Previous Covid-19 diagnoses	Study Group(s)	Outcome(s); Risk Interval; Case Ascertainment	Analysis	Results																																																												
						<p>(For dose 1: aIRR range 8.05 to 10.47; all significant; excess cases 3.3 to 5.2)</p> <p>0-7 d risk interval (12-17 y only)</p> <table> <thead> <tr> <th></th> <th>aIRR (95% CI)</th> <th>Excess risk per million doses</th> </tr> </thead> <tbody> <tr> <td>Pfizer</td> <td>NE (16.88 to NE)</td> <td>29.6</td> </tr> <tr> <td>Dose 2</td> <td>NE (28.83 to NE)</td> <td>54.0</td> </tr> </tbody> </table> <p>0-21 d risk interval (12-17 y only)</p> <table> <thead> <tr> <th></th> <th>aIRR (95% CI)</th> <th>Excess risk per million doses</th> </tr> </thead> <tbody> <tr> <td>Pfizer</td> <td>NE (5.68 to NE)</td> <td>29.6</td> </tr> <tr> <td>Dose 2</td> <td>NE (9.09 to NE)</td> <td>56.7</td> </tr> </tbody> </table> <p>Head-to-head Moderna vs Pfizer in 18-39 y</p> <table> <thead> <tr> <th>(0-7 d)</th> <th>aIRR</th> <th>Excess risk per million doses</th> </tr> </thead> <tbody> <tr> <td>Both doses</td> <td>2.56 (1.32 to 5.03)</td> <td>8.0</td> </tr> <tr> <td>Dose 2</td> <td>2.72 (1.25 to 6.05)</td> <td>13.3</td> </tr> <tr> <td>Dose 2 (males)</td> <td>2.26 (1.00 to 5.19)</td> <td>21.5</td> </tr> </tbody> </table> <table> <thead> <tr> <th>(0-21 d)</th> <th>aIRR</th> <th>Excess risk per million doses</th> </tr> </thead> <tbody> <tr> <td>Both doses</td> <td>2.05 (1.11 to 3.83)</td> <td>7.1</td> </tr> <tr> <td>Dose 2</td> <td>2.19 (1.05 to 4.65)</td> <td>11.5</td> </tr> </tbody> </table> <p>Dose 1 all nonsignificant</p> <p>Head-to-head Moderna vs Pfizer in 18-39 y (without pericarditis)</p> <table> <thead> <tr> <th>(0-7 d)</th> <th>aIRR</th> <th>Excess cases per million doses</th> </tr> </thead> <tbody> <tr> <td>Both doses</td> <td>2.24 (1.09 to 4.63)</td> <td>5.6</td> </tr> <tr> <td>Dose 2</td> <td>2.28 (1.25 to 6.05)</td> <td>13.3</td> </tr> <tr> <td>Dose 2 (males)</td> <td>2.14 (0.93 to 4.98)</td> <td>19.1</td> </tr> </tbody> </table> <table> <thead> <tr> <th>(0-21 d)</th> <th>aIRR</th> <th>Excess cases per million doses</th> </tr> </thead> <tbody> <tr> <td>Both doses</td> <td>1.96 (0.99 to 3.91)</td> <td>5.3</td> </tr> <tr> <td>Dose 2</td> <td>2.19 (0.98 to 4.97)</td> <td>9.4</td> </tr> </tbody> </table> <p>Dose 1 all nonsignificant</p>		aIRR (95% CI)	Excess risk per million doses	Pfizer	NE (16.88 to NE)	29.6	Dose 2	NE (28.83 to NE)	54.0		aIRR (95% CI)	Excess risk per million doses	Pfizer	NE (5.68 to NE)	29.6	Dose 2	NE (9.09 to NE)	56.7	(0-7 d)	aIRR	Excess risk per million doses	Both doses	2.56 (1.32 to 5.03)	8.0	Dose 2	2.72 (1.25 to 6.05)	13.3	Dose 2 (males)	2.26 (1.00 to 5.19)	21.5	(0-21 d)	aIRR	Excess risk per million doses	Both doses	2.05 (1.11 to 3.83)	7.1	Dose 2	2.19 (1.05 to 4.65)	11.5	(0-7 d)	aIRR	Excess cases per million doses	Both doses	2.24 (1.09 to 4.63)	5.6	Dose 2	2.28 (1.25 to 6.05)	13.3	Dose 2 (males)	2.14 (0.93 to 4.98)	19.1	(0-21 d)	aIRR	Excess cases per million doses	Both doses	1.96 (0.99 to 3.91)	5.3	Dose 2	2.19 (0.98 to 4.97)	9.4
	aIRR (95% CI)	Excess risk per million doses																																																																
Pfizer	NE (16.88 to NE)	29.6																																																																
Dose 2	NE (28.83 to NE)	54.0																																																																
	aIRR (95% CI)	Excess risk per million doses																																																																
Pfizer	NE (5.68 to NE)	29.6																																																																
Dose 2	NE (9.09 to NE)	56.7																																																																
(0-7 d)	aIRR	Excess risk per million doses																																																																
Both doses	2.56 (1.32 to 5.03)	8.0																																																																
Dose 2	2.72 (1.25 to 6.05)	13.3																																																																
Dose 2 (males)	2.26 (1.00 to 5.19)	21.5																																																																
(0-21 d)	aIRR	Excess risk per million doses																																																																
Both doses	2.05 (1.11 to 3.83)	7.1																																																																
Dose 2	2.19 (1.05 to 4.65)	11.5																																																																
(0-7 d)	aIRR	Excess cases per million doses																																																																
Both doses	2.24 (1.09 to 4.63)	5.6																																																																
Dose 2	2.28 (1.25 to 6.05)	13.3																																																																
Dose 2 (males)	2.14 (0.93 to 4.98)	19.1																																																																
(0-21 d)	aIRR	Excess cases per million doses																																																																
Both doses	1.96 (0.99 to 3.91)	5.3																																																																
Dose 2	2.19 (0.98 to 4.97)	9.4																																																																
VSD† Aug 21 Dec 14 2020 to Aug 21 2021	Pfizer-BioNTech (57% overall) or Moderna	Total doses 13,334,831 (66.5% fully vaccinated) to 7.1 million people	1. Vaccinated in previous 0-21 d 2. Concurrent previous vaccinees (22 to 42 d previously for similar	Myocarditis/pericarditis/myopericarditis (combined) Risk interval: 0-21 d		<p>Events: 115 aIRR: 1.57 p=0.010 (not meeting p<0.0048 signal)</p> <p><u>Subgroups:</u></p>																																																												

Dataset Dates Country	Vaccines Studied	Sample Size; Demographics; Previous Covid-19 diagnoses	Study Group(s)	Outcome(s); Risk Interval; Case Ascertainment	Analysis	Results																											
USA (Klein 2021b)			individuals after vaccine dose 1 or 2 [most dose 2])			<p>12-39 y 56 cases in 0-21 d risk interval</p> <table border="0"> <tr> <td></td> <td>aIRR</td> <td>Excess risk per million doses</td> </tr> <tr> <td>Both doses</td> <td>5.63 (2.31 to 16.44)</td> <td>8.9</td> </tr> <tr> <td>Dose 2</td> <td>8.31 (3.07 to 28.28)</td> <td>15.5</td> </tr> <tr> <td colspan="3"> </td> </tr> <tr> <td>Pfizer</td> <td>3.62 (1.39 to 11.11)</td> <td>7.2</td> </tr> <tr> <td>Dose 2</td> <td>5.74 (1.98 to 20.52)</td> <td>13.6</td> </tr> <tr> <td colspan="3"> </td> </tr> <tr> <td>Moderna</td> <td>NE (3.32 to NE)</td> <td>12.7</td> </tr> <tr> <td>Dose 2</td> <td>NE (3.79 to NE)</td> <td>19.8</td> </tr> </table> <p>Dose 1 aIRR 2.3 to 3.8 and imprecise for separate vaccines</p> <p>For 0-7 risk interval – see more recent data in Klein Oct 21, 2021</p>		aIRR	Excess risk per million doses	Both doses	5.63 (2.31 to 16.44)	8.9	Dose 2	8.31 (3.07 to 28.28)	15.5	 			Pfizer	3.62 (1.39 to 11.11)	7.2	Dose 2	5.74 (1.98 to 20.52)	13.6	 			Moderna	NE (3.32 to NE)	12.7	Dose 2	NE (3.79 to NE)	19.8
	aIRR	Excess risk per million doses																															
Both doses	5.63 (2.31 to 16.44)	8.9																															
Dose 2	8.31 (3.07 to 28.28)	15.5																															
Pfizer	3.62 (1.39 to 11.11)	7.2																															
Dose 2	5.74 (1.98 to 20.52)	13.6																															
Moderna	NE (3.32 to NE)	12.7																															
Dose 2	NE (3.79 to NE)	19.8																															
VSD† Jun 26 Dec 14 2020 to Jun 26 2021 USA Klein 2021c	Pfizer-BioNTech (57% overall) or Moderna	<p>10,162,227 doses to 6.2 million vaccine-eligible members (≥12 y) (60.7% received at least 1 dose)</p> <p>Females 52.4% Mean age 49 y; 5.5% 12-15 y; 2.8% 16-17 y; 50.4% 18-49 y White non-Hispanic 40.6%</p> <p>Excluded from analysis if COVID-19 diagnosis ≤30 d before vaccination</p>	<ol style="list-style-type: none"> Vaccinated in previous 0-21 d Concurrent previous vaccinees (22 to 42 d previously for similar individuals after vaccine dose 1 or 2 [most dose 2]) Unvaccinated concurrent comparators (same day) <p>Interval between doses NR</p>	<p>Myocarditis/pericarditis/ myopericarditis (combined)</p> <p>Risk interval: 0-21 d and 0-7 d</p> <p>ICD-10 using inclusion and exclusionary codes via clinical expert consultation; cases among 12-39 y confirmed by medical record review</p> <p>ED and in-patient records used</p> <p>Blinding to vaccine status NR</p>	<p>Weekly, rapid cycle analysis</p> <p>Incidence after any dose, after dose 1 and after dose 2</p> <p>Incident rate ratio (IRR) estimated by Poisson regression adjusted for age, sex, race and ethnicity, health plan, and calendar day; 1-sided P < .0048 for statistical signal</p> <p>Excess risk/incidence per million doses (IR – [IR/IRR])</p> <p><u>Exploratory analyses</u> (no prespecified level of significance): by dose and vaccine type; for 12-39 y by dose, vaccine type and with shorter risk intervals</p>	<p>Group 1 vs. 2 Events: 87 vs 39 events Incidence: 131.1 vs. 106.9 per million person-years aIRR: 1.18 (95% CI, 0.79 to 1.79) Excess risk/cases per million doses: 1.2 (95% CI, –2.1 to 3.3)</p> <p><u>Exploratory analyses:</u></p> <p><i>By dose and vaccine type: p > 0.0048 for all</i></p> <p>12-39y: 34 cases (53% 12-24y; 85% male; 82% hospitalized; 71% after dose 2; 7 myocarditis; 6 pericarditis; 21 myopericarditis) Clustering at 0-5 d after vaccine (p<.001) During 0-21 d after vaccination (either dose): Incidence: 141.2 vs. 35.0 cases per million person-years aIRR: 3.74 (95% CI, 1.38 to 12.84) Similar results for each dose but most precise for dose 2 having more data</p> <p>During 0-7 d after vaccination (either dose): Incidences: 321 vs 35 cases per million person-years aIRR: 9.83 (95% CI, 3.35 to 35.77) Excess risk per million doses: 6.3 (95% CI, 4.9 to 6.8) Similar results for each dose but most precise for dose 2 having more data</p> <p>Similar findings in analyses by vaccine type</p>																											

Dataset Dates Country	Vaccines Studied	Sample Size; Demographics; Previous Covid-19 diagnoses	Study Group(s)	Outcome(s); Risk Interval; Case Ascertainment	Analysis	Results
						Group 1 vs 3: Events: 87 vs. 293 Incidence 132 vs. 83 cases per million person-years aIRR: 1.39 (95% CI, 1.05 to 1.82)
US Military Apr 30 Jan 1 to Apr 30 2021 USA Montgomery 2021	Pfizer-BioNTech or Moderna	2,810,00 doses (38% dose 2) Males 100% Median age 25 (20-51) Tested cases for Covid-19 n=0 but all cases after dose 2 (n=3) had previous Covid-19	1. Vaccinated 2. Expected numbers within 30 d after vaccination	Myocarditis Cases identified via referrals to Defense Health Agency clinical specialists and through review of VAERS reports; each case adjudicated using CDC definition for probable Risk interval: all presented within 4 d	Incidence in vaccinated Observed vs expected cases: expected number based on an expected annual incidence ranging from 1-10 per 100 000 person-years (US) to 22 per 100 000 person-years (internationally); presenting within a 30-day period after vaccination.	Events: 23 (20 after dose 2) Observed vs expected: Total doses: 23 v vs 2 to 52 Dose 2: 20 vs 1 to 20 Dose 2 to military members: 19 vs 0 to 10 Dose 2 to male military members: 19 vs 0 to 8 Incidence: Total doses: 0.8 per 100,000 doses Dose 2: 1.9 per 100,000 doses Dose 2 to military members: 3.5 per 100,000 doses Dose 2 to male military members: 4.4 per 100,000 doses
Providence Health May 25 Up to May 25 2021 USA Diaz 2021	Pfizer, Moderna, Janssen At least one dose (23.5% more than 1)	N=2,000,287 Female 58.9% Median age 57 y (IQR 40-70)	1. Individuals vaccinated with at least 1 dose 2. Unvaccinated individuals Jan 19 – Jan21	Myocarditis, Pericarditis w/o myocarditis Emergency department or inpatient encounters with diagnoses of myocarditis/myopericarditis, or pericarditis Patients with previous diagnoses (cardiac, immunological, infectious) excluded Risk interval: 30d	Change/excess in incidence between periods	Excess incidence of myocarditis/myopericarditis: 1.0 (0.61-1.54) per 100,000 vaccinees Excess incidence of pericarditis: 1.8 (1.30-2.55) per 100,000 vaccinees
KPSC Jul 20 Dec 14 2021 to Jul 20 2021 USA Simone 2021	BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (93.5% fully vaccinated)	KPSC members ≥18y Vaccinated group n=2,392,924 Median age 49y (IQR: 34-64y) Age <40 y: 35.7% Females 54.0%	1. Vaccinated 2. Concurrent unvaccinated 3. Vaccinated individuals during a 10-day period 1 year prior to vaccination	Myocarditis Reports from clinicians to the KPSC Regional Immunization Practice Committee and by identifying hospitalization within 10 days of vaccine administration with a	Incidence rates and 95% confidence intervals (CIs) IRR 1 vs 2, 1 vs 3	Observed incidence: Dose 1: 0.8 (0.2-3.3) cases per 1 million first doses Dose 2: 5.8 (3.4-10) cases per 1 million second doses Unvaccinated: 2.2 (1.7-2.7) cases per million people 100% cases men IRR (95% CI): 1 v 2 Dose 1: 0.38 (0.05-1.40) Dose 2: 2.7 (1.4-4.8)

Dataset Dates Country	Vaccines Studied	Sample Size; Demographics; Previous Covid-19 diagnoses	Study Group(s)	Outcome(s); Risk Interval; Case Ascertainment	Analysis	Results
		Black 6.7%; Hispanic 37.8%; Asian 14.3% Unvaccinated group: n=1 577 741, median (IQR) age was 39 (28-53) years Age <40y: 53.7% Females: 49.1% Black 8.8%; Hispanic 39.2%; Asian 6.6%		discharge diagnosis of myocarditis All cases were independently adjudicated by at least 2 cardiologists. Risk interval: 10d		IRR 1 v 3 Dose 1: 1.0 (0.1-13.8) Dose 2: 3.3 (1.0-13.7)
Israel MOH* May 31 Dec 20 2020 to May 31 2021 Israel Mevorach, 2021	Pfizer-BioNTech 2 doses to 5.12 million people	Surveillance population 9,289,765 Israeli residents ≥16 y 29 of 98 cases in unvaccinated population had confirmed Covid-19 (timing NR); NR for vaccinated Age, sex, race/ethnicity NR None of the post-vaccination cases had concurrent Covid-19 via symptoms or PCR; 35/39 had negative serology tests	1. Received dose 1 (n=5,442,696) 2. Received dose 2 (n=5,125,635) 3. Concurrent unvaccinated persons matched by date 4. Historical controls from 2017-2019 Interval between doses 21 d	Myocarditis/myopericarditis ICD-9 codes 422.0-9x and 429.0x; cases 12-29 yrs old confirmed by medical record review using Brighton Criteria via consensus Assessors not blinded to vaccine status Cases of pericarditis without myocarditis were excluded Risk interval: 21 d for dose 1 and 30d for dose 2	Incidence in groups 1 and 2 (cumulative risks) Risk difference (incidence) between 1 vs 2 Standardized incidence ratio of observed-to-expected (historical controls) Attributable risk to dose 2 IRR group 2 vs 3 (weighted by age and sex) Subgroups: sex, 5-yr age categories <30; 10 yr after 30; shorter risk interval 0-7 d	Total events in groups 1 and 2: 142 (136 definitive or probable [117 after dose 2], used for analysis except for standardized IR); group 3: 101 Incidence: dose 1: 0.35 per 100,000 persons; dose 2: 2.28 per 100,000 persons Risk difference dose 2 – dose 1: 1.76 per 100,000 persons (95% CI, 1.33 to 2.19) Standardized incidence ratio: group 1 vs 4 1.42 (95% CI, 0.92 to 2.10); group 2 vs 4: 5.34 (95% CI, 4.48 to 6.40) aIRR group 2 vs 3: 2.35 (95% CI, 1.10 to 5.02) <u>Subgroup analyses</u> Males vs females: Incidence: dose 1: 0.64 vs 0.07 per 100,000 persons dose 2: 3.83 vs. 0.46 per 100,000 persons Risk difference dose 2 – dose 1: 3.19 (95% CI, 2.37 to 4.02) vs. 0.39 (95% CI, 0.10 to 0.68) IRR: NR By age categories: Males Dose 1 incidence per 100,000 persons 16-19 y 1.34 20-24 y 1.91 25-29y 1.22 30-39 y 0.41

Dataset Dates Country	Vaccines Studied	Sample Size; Demographics; Previous Covid-19 diagnoses	Study Group(s)	Outcome(s); Risk Interval; Case Ascertainment	Analysis	Results
						<p>40-49y 0.65 ≥50y 0.10 Dose 2 incidence 16-19 y 15.07 20-24 y 10.86 25-29 y 6.99 30-39 y 3.69 40-49 y 1.15 ≥50 y 0.21 aIRR 16-19 y 8.96 (95% CI, 4.50 to 17.83); 20-24 y 6.13 (95% CI 3.16 to 11.88); 25-29 y 3.58 (95% CI 1.82 to 7.01); ≥30 y 1.00 (95% CI, 0.61 to 1.64)</p> <p>Females Dose 1 incidence 16-39 y 0 40-49 y 0.21 ≥50 y 0.09 Dose 2 incidence 16-19 y 1.00 20-24 y 2.16 25-29 y 0 30-39 y 0.22 40-49 y 0.45 ≥50 y 0.19 IRR 20-24 y 7.56 (95 CI, 1.47 to 8.96); others imprecise</p> <p>Shorter risk interval (7 d after dose 2): Males 16-19 y: Risk difference: 13.62 per 100,000 persons (95% CI, 8.31 to 19.03) IRR: 31.90 (95% CI, 15.88 to 64.08)</p>
<p>Clalit Health** May 24a Dec 20 2020 to May 24 2021 Israel Witberg, 2021</p>	<p>Pfizer- BioNTech 94% received 2 doses</p>	<p>2,558,421 ≥16 y receiving at least 1 dose (94% 2 doses) 2 cases had Covid-19 (125 and 186 d) prior to vaccine but NR if any others and NR if active testing of cases</p>	<p>1. Received 1 dose (n=2,558,421) Interval between doses 21 d</p>	<p>Myocarditis Risk interval: 42 d after dose 1 ICD-9 (codes 422, 429.0, 398.0, and 391.2 and their respective subcodes), with adjudication by cardiologists using medical and CDC case definition, with consensus</p>	<p>Incidence after dose 1 or 2 using Kaplan–Meier analysis Subgroups: Sex; Ages 16-29 y; ≥30 y</p>	<p>Events: 54 (of 159 potential cases; 37 after dose 2; with 17/37 >7 days post dose 2) Incidence: 2.13 cases per 100,000 persons (95% CI: 1.56 to 2.70) <u>Subgroup analysis</u> Males vs females: Incidence: 4.12 (95% CI: 2.99 to 5.26) vs. 0.23 (95% CI: 0 to 0.49) <u>By age categories:</u> Overall 16-29 y: 5.49 per 100,000 persons (95% CI: 3.59 to 7.39) Overall ≥30 y: 1.13 per 100,000 persons (95% CI: 0.66 to 1.60) Males 16-29 y: 10.69 per 100,000 persons (95% CI: 6.93 to 14.46)</p>

Dataset Dates Country	Vaccines Studied	Sample Size; Demographics; Previous Covid-19 diagnoses	Study Group(s)	Outcome(s); Risk Interval; Case Ascertainment	Analysis	Results
				Unblinded to vaccine status (all vaccinated and author adjudicating)		Males ≥ 30 y: 2.11 per 100,000 persons (95% CI, 1.19 to 3.04) Females 16-29 y: 0.34 per 100,000 persons (95% CI, 0 to 1) Females ≥ 30 y: 0.20 per 100,000 persons (95% CI, 0 to 0.48)
Clalit Health** May 24b Dec 20 2020 to May 24 2021 Israel Barda, 2021	Pfizer-BioNTech NR how may had 1 vs 2 doses	Surveillance population 1,877,624 ≥ 16 y Excluded people with previous events, residing in nursing homes, healthcare workers, no BMI or residential area data Mean age 38 y Females 48% Previous Covid-19 cases excluded	1. Received 1 dose (n=884,828) 2. Concurrent unvaccinated, matched 1:1 by age, sex, place of residence, socioeconomic status, population sector (general Jewish, Arab, or ultra-Orthodox Jewish), number of preexisting conditions at risk for severe Covid-19. (n=884,828) Interval between doses 21 d	Myocarditis & pericarditis after at least 1 dose Risk interval: 42 d after dose 1 ICD-9 codes (422, 429.0, 398.0, 391.2, 420) after the index date Blinding NR	Incidence using Kaplan-Meier estimator Risk difference Risk Ratio	Events in group 1 vs 2: myocarditis 21 (91% male; median age 25y [IQR 20-34]) vs 6; pericarditis: 27 vs 18 Risk difference (all ages): myocarditis: 2.7 events per 100,000 persons (95% CI, 1.0 to 4.6); pericarditis: 1.0 events per 100,000 persons (95% CI, -1.6 to 3.4) RR: myocarditis: 3.24 (95% CI, 1.55 to 12.44); pericarditis: 1.27 (95% CI, 0.68 to 2.31)
Israeli Defense Forces May 7 Dec 28 2020 to Mar 7 2021 Israel Levin, 2021	Pfizer-BioNTech 138,000 military personnel receiving 2 doses	138,000 NR NR	1. Vaccinated with 2 doses (n=138,000) Interval between doses NR	Myocarditis Medical record review, requiring ECG, echocardiography, or MRI findings Risk interval: 7 d after dose 2 Not blinded	Crude cumulative incidence	Events: 7 confirmed in risk interval (100% male; Age 18-24) Incidence: 5.07 per 100,000 people
Genesis Healthcare*** Feb 14 Dec 18 2020 to Feb 14 2021 USA Bardenheier, 2021a	Moderna or Pfizer-BioNTech All had 1 dose	20,918 nursing home residents Females 61.9% <65 y 18.5% African American or Latinx 16.9% Excluded if Covid-19 +ve within 20 d of vaccination, or treated	1. No prior infection at vaccination (n=13,163) 2. Symptomatic infection >20 days before vaccination (n=5,617) 3. Asymptomatic infection >20 days before vaccination (n=2,138) 4. Unvaccinated (from Bardenheier, 2021b) Interval between doses NA	Myocarditis/pericarditis Risk interval: 15 days after dose 1 Active, prospective surveillance; medical record review for ICD-10-CM codes, confirmed by physician chart review, using Brighton Collaboration Criteria	Incidence (if events) Comparisons between groups by multilevel logistic regression that adjusted for clustering and applied propensity scoring for age, sex, pre-existing conditions	Events: group 1 vs 2 vs 3: 0 vs. 0 vs. 0

Dataset Dates Country	Vaccines Studied	Sample Size; Demographics; Previous Covid-19 diagnoses	Study Group(s)	Outcome(s); Risk Interval; Case Ascertainment	Analysis	Results
		with SARS-CoV-2 monoclonal antibodies within 90 days before vaccination		Blinding NR		
Genesis Healthcare*** Jan 3 Dec 18 2020 to Jan 3 2021 USA Bardenheier, 2021b	Moderna or Pfizer- BioNTech (70.6%) 1 st dose or 2 nd dose	21,222 nursing home residents Females 61.9% <65 y 18.8 African American or Latinx 18% Excluded if Covid-19 +ve within 20 d of vaccination, or treated with SARS-CoV-2 monoclonal antibodies within 90 days before vaccination	1. After dose 1 (n=8553) 2. After dose 2 (n=8371) 3. Unvaccinated (n=11072) Interval between doses 3 to 6 weeks	Myocarditis Active, prospective surveillance; medical record review for ICD-10 codes, confirmed by physician chart review, using Brighton Collaboration Criteria Blinding NR	Incidence IRR, adjusted for age, sex, pre-existing conditions	Events: 0 vs. 0 vs. 0

Table A2. Study characteristics of observational studies using data from passive surveillance systems (question 1)

Dataset Dates of data Country of Data	Vaccines Studied	Outcome(s); Case Ascertainment & Risk Interval	Analysis	Results																																																																																																																																											
VAERS* Oct 6 Up to Oct 6, 2021 USA Su, 2021	Pfizer-BioNTech, Moderna and Janssen	Myopericarditis (myocarditis +/- pericarditis); pericarditis Screening via 30 MedDRA terms and ICD-10; all analyzed reports verified to meet CDC case definition by provider interview or medical record review Risk interval: 7 d	Crude reporting rates of confirmed cases of myopericarditis after each dose	Total events: 2,459 myopericarditis (1,181 have been verified and 935 occurred in 0-6 d after vaccination; 877 pericarditis (366,062,239 doses of mRNA vaccines) For myopericarditis: 67% Pfizer; 29% Moderna; 76% after dose 2 (50 preliminary reports after Janssen not in analysis) <u>Reporting rates of myopericarditis per 1 million doses administered (N=935 verified cases):</u> <table border="1"> <thead> <tr> <th rowspan="2">Ages</th> <th colspan="2">Pfizer</th> <th colspan="2">Moderna</th> </tr> <tr> <th>Dose 1</th> <th>Dose 2</th> <th>Dose 1</th> <th>Dose 2</th> </tr> </thead> <tbody> <tr> <td>12-15</td> <td>2.3*</td> <td>21.5</td> <td>0.0</td> <td>not calculated</td> </tr> <tr> <td>16-17</td> <td>2.8</td> <td>37.4</td> <td>0.0</td> <td>not calculated</td> </tr> <tr> <td>18-24</td> <td>1.2</td> <td>18.1</td> <td>3.1</td> <td>20.7</td> </tr> <tr> <td>25-29</td> <td>0.7</td> <td>5.7</td> <td>1.8</td> <td>11.2</td> </tr> <tr> <td>30-39</td> <td>0.6</td> <td>2.8</td> <td>1.4</td> <td>3.6</td> </tr> <tr> <td>40-49</td> <td>0.2</td> <td>1.5</td> <td>0.2</td> <td>2.1</td> </tr> <tr> <td>50-64</td> <td>0.3</td> <td>0.4</td> <td>0.5</td> <td>0.5</td> </tr> <tr> <td>65+</td> <td>0.1</td> <td>0.2</td> <td>0.0</td> <td>0.3</td> </tr> </tbody> </table> <u>Males (N=797):</u> <table border="1"> <thead> <tr> <th>Ages</th> <th>Dose 1</th> <th>Dose 2</th> <th>Dose 1</th> <th>Dose 2</th> </tr> </thead> <tbody> <tr> <td>12-15</td> <td>4.2</td> <td>39.9</td> <td>0.0</td> <td>not calculated</td> </tr> <tr> <td>16-17</td> <td>5.7</td> <td>69.1</td> <td>0.0</td> <td>not calculated</td> </tr> <tr> <td>18-24</td> <td>2.3</td> <td>36.8</td> <td>6.1</td> <td>38.5</td> </tr> <tr> <td>25-29</td> <td>1.3</td> <td>10.8</td> <td>3.4</td> <td>17.2</td> </tr> <tr> <td>30-39</td> <td>0.5</td> <td>5.2</td> <td>2.3</td> <td>6.7</td> </tr> <tr> <td>40-49</td> <td>0.3</td> <td>2.0</td> <td>0.2</td> <td>2.9</td> </tr> <tr> <td>50-64</td> <td>0.2</td> <td>0.3</td> <td>0.5</td> <td>0.6</td> </tr> <tr> <td>65+</td> <td>0.2</td> <td>0.1</td> <td>0.1</td> <td>0.3</td> </tr> </tbody> </table> <u>Females (N=138):</u> <table border="1"> <thead> <tr> <th>Ages</th> <th>Dose 1</th> <th>Dose 2</th> <th>Dose 1</th> <th>Dose 2</th> </tr> </thead> <tbody> <tr> <td>12-15</td> <td>0.4</td> <td>3.9</td> <td>0.0</td> <td>0.0</td> </tr> <tr> <td>16-17</td> <td>0.0</td> <td>7.9</td> <td>0.0</td> <td>0.0</td> </tr> <tr> <td>18-24</td> <td>0.2</td> <td>2.5</td> <td>0.6</td> <td>5.3</td> </tr> <tr> <td>25-29</td> <td>0.2</td> <td>1.2</td> <td>0.4</td> <td>5.7</td> </tr> <tr> <td>30-39</td> <td>0.6</td> <td>0.7</td> <td>0.5</td> <td>0.4</td> </tr> <tr> <td>40-49</td> <td>0.1</td> <td>1.1</td> <td>0.2</td> <td>1.4</td> </tr> <tr> <td>50-64</td> <td>0.3</td> <td>0.5</td> <td>0.5</td> <td>0.4</td> </tr> <tr> <td>65+</td> <td>0.1</td> <td>0.3</td> <td>0.0</td> <td>0.3</td> </tr> </tbody> </table> *Reporting rates exceed background incidence (bolded data above) An estimated 1–10 cases of myocarditis per 100,000 person years occurs among people in the United States, regardless of vaccination status; adjusted for the 7-day risk period, this estimated background is 0.2 to 1.9 per 1 million person 7-day risk period	Ages	Pfizer		Moderna		Dose 1	Dose 2	Dose 1	Dose 2	12-15	2.3*	21.5	0.0	not calculated	16-17	2.8	37.4	0.0	not calculated	18-24	1.2	18.1	3.1	20.7	25-29	0.7	5.7	1.8	11.2	30-39	0.6	2.8	1.4	3.6	40-49	0.2	1.5	0.2	2.1	50-64	0.3	0.4	0.5	0.5	65+	0.1	0.2	0.0	0.3	Ages	Dose 1	Dose 2	Dose 1	Dose 2	12-15	4.2	39.9	0.0	not calculated	16-17	5.7	69.1	0.0	not calculated	18-24	2.3	36.8	6.1	38.5	25-29	1.3	10.8	3.4	17.2	30-39	0.5	5.2	2.3	6.7	40-49	0.3	2.0	0.2	2.9	50-64	0.2	0.3	0.5	0.6	65+	0.2	0.1	0.1	0.3	Ages	Dose 1	Dose 2	Dose 1	Dose 2	12-15	0.4	3.9	0.0	0.0	16-17	0.0	7.9	0.0	0.0	18-24	0.2	2.5	0.6	5.3	25-29	0.2	1.2	0.4	5.7	30-39	0.6	0.7	0.5	0.4	40-49	0.1	1.1	0.2	1.4	50-64	0.3	0.5	0.5	0.4	65+	0.1	0.3	0.0	0.3
Ages	Pfizer		Moderna																																																																																																																																												
	Dose 1	Dose 2	Dose 1	Dose 2																																																																																																																																											
12-15	2.3*	21.5	0.0	not calculated																																																																																																																																											
16-17	2.8	37.4	0.0	not calculated																																																																																																																																											
18-24	1.2	18.1	3.1	20.7																																																																																																																																											
25-29	0.7	5.7	1.8	11.2																																																																																																																																											
30-39	0.6	2.8	1.4	3.6																																																																																																																																											
40-49	0.2	1.5	0.2	2.1																																																																																																																																											
50-64	0.3	0.4	0.5	0.5																																																																																																																																											
65+	0.1	0.2	0.0	0.3																																																																																																																																											
Ages	Dose 1	Dose 2	Dose 1	Dose 2																																																																																																																																											
12-15	4.2	39.9	0.0	not calculated																																																																																																																																											
16-17	5.7	69.1	0.0	not calculated																																																																																																																																											
18-24	2.3	36.8	6.1	38.5																																																																																																																																											
25-29	1.3	10.8	3.4	17.2																																																																																																																																											
30-39	0.5	5.2	2.3	6.7																																																																																																																																											
40-49	0.3	2.0	0.2	2.9																																																																																																																																											
50-64	0.2	0.3	0.5	0.6																																																																																																																																											
65+	0.2	0.1	0.1	0.3																																																																																																																																											
Ages	Dose 1	Dose 2	Dose 1	Dose 2																																																																																																																																											
12-15	0.4	3.9	0.0	0.0																																																																																																																																											
16-17	0.0	7.9	0.0	0.0																																																																																																																																											
18-24	0.2	2.5	0.6	5.3																																																																																																																																											
25-29	0.2	1.2	0.4	5.7																																																																																																																																											
30-39	0.6	0.7	0.5	0.4																																																																																																																																											
40-49	0.1	1.1	0.2	1.4																																																																																																																																											
50-64	0.3	0.5	0.5	0.4																																																																																																																																											
65+	0.1	0.3	0.0	0.3																																																																																																																																											
VAERS* Jun 30 Up to Jun 30 2021	Pfizer-BioNTech or Moderna	Myocarditis	Crude reporting rates after dose 2 Subgroups by age and sex	Overall ≥18 yrs: 3.5 cases per million second doses <u>Subgroups (all after dose 2):</u>																																																																																																																																											

Dataset Dates of data Country of Data	Vaccines Studied	Outcome(s); Case Ascertainment & Risk Interval	Analysis	Results
USA Rosenblum, 2021	After dose 2, timing NR	Cases in persons aged 18–29 yrs were individually reviewed and confirmed to meet CDC case definitions Risk interval: 42 d		Females 18-29 yrs: 3-4 cases per million second doses 30-49 yrs: 1-2 cases per million second doses 50-64 yrs: 1 case per million second doses ≥65 yrs: <1 case per million second doses Males 18-29 yrs: 22-27 cases per million second doses 30-49 yrs: 5-6 cases per million second doses 50-64 yrs: 1 case per million second doses ≥65 yrs: 1 case per million second doses
VAERS* Jun 11 Up to Jun 11 2021 USA Gargano 2021	Pfizer-BioNTech or Moderna After dose 2, timing NR	Myocarditis Note: Subset of confirmed cases described and included in KQ2 Risk interval: 7 d	Crude reporting rates (i.e., using confirmed and unconfirmed cases), after dose 2	Males 12-29 yrs: 40.6 cases per million second doses Males 12-17 yrs: 62.8 cases per million second doses Males 18-24 yrs: 50.5 cases per million second doses Males ≥30 yrs: 2.4 cases per million second doses Females 12-29 yrs: 4.2 cases per million second doses Females ≥30 yrs: 1.0 cases per million second doses
VAERS* Aug 6 Up to Aug 6 2021 US Lane 2021	Pfizer-BioNTech, Moderna At least one dose (UK, EEA) or 2 doses (US); schedule NR.	Myocarditis and pericarditis Events labelled "Myocarditis" or "Pericarditis" Risk interval: None applied (date of vaccine launch to datalockpoint)	Crude reporting rates per million people receiving at least one dose (UK, EEA) or receiving both doses (US)	<u>UK</u> Pfizer/BioNTech: 7.93 cases of myocarditis and 6.73 cases pericarditis per million vaccinees Moderna: 2.07 cases of myocarditis and 1.79 cases of pericarditis per million vaccinees <u>EEA</u> Pfizer/BioNTech: 4.23 cases of myocarditis and 2.87 cases of pericarditis per million vaccinees Moderna: 6.15 cases of myocarditis and 3.84 cases of pericarditis per million vaccinees <u>US (after dose 2)</u> Pfizer/BioNTech: 6.47 cases of myocarditis and 3.53 cases of pericarditis per million vaccinees Moderna: 3.65 cases of myocarditis and 2.69 cases of pericarditis per million vaccinees
VAERS* Jun 18a Jan 1 to Jun 18 2021 USA Høeg 2021	Pfizer-BioNTech or Moderna (but only 1 of 257 cases since not approved for <18y at that time) Schedule NR	Myocarditis "Myocarditis," "pericarditis," "myopericarditis" or "chest pain" in the symptom notes; "troponin" required element in the laboratory data. CDC working case definition of probable myocarditis Risk interval: Any timing	Crude rates per million vaccinees Cases with an unknown dose number were assigned to dose 1 or dose 2 in the same proportion as the known doses: 15% occurred following dose 1 and 85% occurred following dose 2	Events: 257 (92% within 5 d; 90% males) <u>At least Dose 1</u> Males 12-15 yrs: 12.0 per million vaccinees Males 16-17 yrs: 8.2 per million vaccinees Females 12-15 yrs: 0 per million vaccinees Females 16-17 yrs: 2.0 per million vaccinees <u>Dose 2</u> Males 12-15 yrs: 162.2 per million vaccinees Males 16-17 yrs: 94.0 per million vaccinees Females 12-15 yrs: 13.0 per million vaccinees Females 16-17 yrs: 13.4 per million vaccinees
VAERS* Jun 18b USA Lazaros 2021	AstraZeneca Janssen Moderna Pfizer-BioNTech	Pericarditis Ascertainment NR	Crude rate per million vaccine doses Raw data available to calculate crude age and sex subgroup rates if needed.	<u>EEA</u> AstraZeneca: 2.604 per million doses Janssen: 2.530 per million doses Total vectored: 2.596 per million doses Moderna: 4.023 per million doses Pfizer-BioNTech: 1.613 per million doses

Dataset Dates of data Country of Data	Vaccines Studied	Outcome(s); Case Ascertainment & Risk Interval	Analysis	Results
	Dose and schedule not specified.			Total mRNA: 1.882 per million doses
CAEFISS & CVP Up to Oct 8 2021 Canada PHAC 2021	AstraZeneca, Moderna (≥12 y), Pfizer-BioNTech (≥12 y) Dose and schedule not specified.	Myocarditis or pericarditis Cases meeting Level 1-4 to Brighton Criteria of Diagnostic Certainty (not all probable or definitive) Risk interval: Any timing	Reported rates per 100,000 doses administered	Events: 913 Moderna: 2.51 cases per 100,000 doses Pfizer-BioNTech: 1.37 cases per 100,000 doses AstraZeneca: 0.72 cases per 100,000 doses
Yellow Card Oct 13 Dec 9 2020 to Oct 13 2021 UK Medicines & Healthcare Products Regulatory Agency 2021	AstraZeneca, Moderna, Pfizer-BioNTech After dose 1 or 2; schedule NR	Myocarditis and pericarditis (including those from viral/other infective causes) Ascertainment NR Risk interval: NR	Reporting rates per million doses	<u>Overall</u> Pfizer-BioNTech: myocarditis 8 cases per million doses; pericarditis 6 cases per million doses Moderna: myocarditis 32 cases per million doses; pericarditis 19 cases per million doses AstraZeneca: myocarditis 3 cases per million doses; pericarditis 4 cases per million doses <u>Subgroups:</u> Myocarditis/pericarditis <18 yrs Pfizer-BioNTech: 10 cases per million doses Moderna: 0 cases AstraZeneca: 0 cases 18-49 yrs Pfizer-BioNTech: 18 cases per million doses Moderna: 44 cases per million doses AstraZeneca: 8 cases per million doses ≥50 yrs Pfizer-BioNTech: 5 cases per million doses Moderna: 29 cases per million doses AstraZeneca: 4 cases per million doses
Israel MOH* May 30 Dec 2020 to May 30 2021 Israel	Pfizer-BioNTech (≥16 y) Dose 1 and 2; schedule NR	Myocarditis Ascertainment NR Risk interval: 30 d after dose 2	Crude number of cases and doses	Dose 1: 27 cases of 5,401,150 vaccinated individuals (5 per million) (11 had pre-existing conditions) Within 30 d after dose 2: 121 cases of 5,049,424 vaccinated individuals (24 per million) (60 had pre-existing conditions)
Eudra Vigilance Oct 19** Up to Oct 19 2021 EEA European Medicines Agency 2021	AstraZeneca Janssen Moderna Pfizer-BioNTech Dose and schedule NR	Myocarditis, pericarditis Ascertainment NR Risk interval: NR	Crude number of case and doses	<u>Overall:</u> Moderna: 1578 cases of myocarditis and 850 cases of pericarditis across 61,172,753 doses administered† (25.8 per million & 13.9 per million) Pfizer: 3610 cases of myocarditis and 2883 cases of pericarditis across 424,162,518 doses administered† (8.5 per million & 6.8 per million) AstraZeneca: 320 cases of myocarditis and 416 cases of pericarditis across 68,799,957 doses administered† (4.7 per million & 6.0 per million) Janssen: 103 cases of myocarditis and 101 cases of pericarditis across 15,782,596 doses administered† (6.5 per million & 6.4 per million) <u>Age <18y</u>

Dataset Dates of data Country of Data	Vaccines Studied	Outcome(s); Case Ascertainment & Risk Interval	Analysis	Results
				Moderna: 32 reports of myocarditis across 531,050 people receiving at least one dose† (60.3 events per million) Pfizer: 369 reports of myocarditis across 8,874,141 people receiving at least one dose† (41.6 events per million)

*Indicates passive surveillance system with mandatory/legal reporting requirements for healthcare providers of adverse events after COVID-19 vaccines.

†Number of administered vaccine doses from European Center for Disease Control (ECDC), up to end of Week 41 2021 (Oct 16 2021). Period of vaccine doses is shorter than event reporting to account for time period between receiving vaccine and experiencing the event of interest (i.e., individuals vaccinated on October 19 are unlikely to be reporting myocarditis as an AE on that same day)

Table A3. Summary of risk of bias assessments for observational studies/surveillance data (question 1)

Dataset	Were the two groups similar and recruited from the same population?	Was vaccination status measured in a reliable or valid way?	Were confounding factors identified and appropriately addressed in design or analysis?	Were the outcomes measured in a valid and reliable way?	Was the follow up time long enough for outcomes to occur?	Were the large majority of cases likely to have been identified?	Overall assessment of risk of bias
Active Surveillance Studies							
VSD Jun 26 Klein 2021 Ref ID 22	Y	Y	U	Y	Y	Y	Some concerns
Israel MOH May 31 Mevorach 2021 Ref ID 3440	Y	U	N	Y	Y	Y	Some concerns
Clalit Health May 24a Witberg Ref ID 3441	NA	Y	Y	Y	Y	Y	Low
Clalit Health May 24b Barda 2021 Ref ID 1282	Y	Y	Y	Y	Y	Y	Low
Israeli Defense Forces May 7 Levin 2021 Ref ID 512	NA	Y	N	Y	N	Y	Some concerns
Genesis Healthcare Feb 14 Bardenheier 2021a Ref ID 144	Y	Y	Y	Y	U	Y	Some concerns
Genesis Healthcare Jan 3 Bardenheier, 2021b ref ID 1972	Y	Y	Y	Y	U	Y	Some concerns
KPSC Jul 2 Simone 2021 Ref ID 22	Y	Y	U	Y	U	Y	Some concerns
Providence Health May 25 Diaz 2021 Ref ID 525	Y	Y	N	U	N	Y	High
VSD Oct 9 (Klein 2021 Oct ACIP)	Y	Y	U	Y	Y	Y	Some concerns
VSD Aug 21	Y	Y	U	Y	Y	Y	Some concerns

Klein 2021 Aug ACIP)							
Passive Surveillance Studies							
VAERS Oct 6 Su, 2021 (ACIP Oct 20-21 2021 meeting)	NA	N	N	Y	Y	N	High
VAERS Jun 30 Rosenblum, 2021	NA	N	N	U	U	N	High
VAERS Jun 11 Gargano 2021	NA	N	N	U	Y	N	High
VAERS Aug 6 Lane 2021	NA	N	N	N	U	N	High
VAERS Jun 18a Høeg 2021	NA	N	N	U	U	N	High
VAERS Jun 18b Lazaros 2021	NA	U	N	U	U	N	High
CAEFISS & CVP PHAC 2021	NA	U	N	N	N	U	High
Yellow Card Oct 13 Medicines & Healthcare Products Regulatory Agency 2021	NA	U	N	U	U	N	High
Israel MOH May 30 Israel Ministry of Health 2021	NA	U	N	U	Y	U	High
EudraVigilance Oct 19 European Medicines Agency 2021	NA	Y	N	U	U	N	High

Table A4. Study characteristics of randomized controlled trials (question 1)

Trial name; Author (year); Country (number of sites); Dates of enrolment Funding	Eligibility, Randomization & Blinding	Study Arms		Baseline Demographics	Outcome(s); Safety Assessment	Analysis	Results
		Vaccine arm	Placebo arm				
Teen COVE trial, Phase 2/3,	Included adolescents 12-17 y	mRNA-1273 (Moderna), 2 doses 28 d apart	Saline placebo 2 doses 28 d apart	Total randomized: 3,732	Myocarditis & pericarditis	Safety analysis included all	Myocarditis: 0 Pericarditis: 0

Trial name; Author (year); Country (number of sites); Dates of enrolment Funding	Eligibility, Randomization & Blinding	Study Arms		Baseline Demographics	Outcome(s); Safety Assessment	Analysis	Results
		Vaccine arm	Placebo arm				
<p>Ali (2021)</p> <p>USA (26)</p> <p>Dec 9, 2020 – Feb 28, 2021</p> <p>USA (26)</p> <p>Industry-funded</p>	<p>Exclusions: travel outside of USA 28 d prior to screening; acute illness or fever 24 h prior to or at screening; previous administration of an investigational SARS-CoV-2 vaccine; pregnant or breastfeeding.</p> <p>Randomized 2:1; centralized interactive response technology system</p> <p>Study personnel and participants were blinded; pharmacists and vaccine administrators unblinded.</p>	<p>100 mcg per 0.5 ml dose</p> <p>Randomized: 2,489 Dose 1: 2,486 Dose 2: 2,480</p> <p>Safety population: 2,486 Withdrawals: After dose 1: 18 After dose 2: 188</p>	<p>0.5 ml per dose</p> <p>Randomized: 1,243 Dose 1: 1,240 Dose 2: 1,222</p> <p>Safety population: 1,240</p> <p>Withdrawals: After dose 1: 6 After dose 2: 57</p>	<p>Total safety population: 3,726</p> <p>Male 51% Mean age 14.3 y 12-15 y: 74% 16-17 y: 26% White 84%</p> <p>Baseline SARS-CoV-2 status: Positive: 216 (6%), similar between arms; Missing: 268 (7%), similar between arms</p>	<p>Solicited local and systemic adverse reactions during 7 d after each injection;</p> <p>Unsolicited adverse events (AEs), defined as any event not present before exposure to study vaccination or any event already present that worsens in intensity or frequency after exposure, observed or reported during 28 d after each injection;</p> <p>AEs leading to discontinuation from a dose and/or study withdrawal, medically attended (MAEs) and serious AE (SAEs), throughout study period</p> <p>Unblinded safety data reviewed by independent data and safety monitoring board</p>	<p>participants who received at least one injection, according to treatment group</p>	
<p>COVE trial, Phase 3</p> <p>Baden (2021; primary publication) & El-Sahly (2021)</p> <p>Jul 27, 2020 – Oct 23, 2020</p> <p>USA (99)</p> <p>Industry-funded</p>	<p>Included adults ≥18 y at appreciable risk of acquiring infection or high risk of severe COVID-19, or both;</p> <p>Exclusions: immunosuppression or received systemic immunosuppressant/immune-modifying drugs for >14 d total in prior 6 mos; known history of SARS-CoV-2 infection; pregnant or breastfeeding,</p>	<p>mRNA-1273 (Moderna) 2 doses 28 d apart 100 mcg per 0.5 ml dose</p> <p>Randomized: 15,210 Dose 1: 15,181 Dose 2: 14,711</p> <p>Safety population (unsolicited AEs): 15,185</p> <p>Withdrawals: 233 (45 discontinued study due to SARS-CoV-2 diagnosis)</p>	<p>Saline placebo 2 doses 28 d apart 0.5 ml dose</p> <p>Randomized: 15,210 Dose 1: 15,170 Dose 2: 14,617</p> <p>Safety population (unsolicited AEs): 15,166</p> <p>Withdrawals: 290 (69 discontinued study due to SARS-CoV-2 diagnosis)</p>	<p>Total randomized: 30,420 Total safety population: 30,351</p> <p>Male 52.6% Mean age 51.4 y White 79.2% 18 to <65 y at risk: 16.7% 18 to <65 y not at risk: 58.6% ≥65 y: 24.8% Significant cardiac disease 4.9% HIV infection 0.6%</p> <p>Baseline SARS-CoV-2 status:</p>	<p>Solicited local and systemic adverse reactions during 7 d following each injection;</p> <p>Unsolicited adverse events (AEs) for 28 d following each injection, including treatment-emergent AE (any event during study not present before exposure to injection or any event already present that worsens after exposure to study vaccine;</p>	<p>Safety analysis included all participants who received at least one injection, according to product received.</p>	<p>From associated publication:</p> <p>Myocarditis: 0 Pericarditis: 2 (68 d & 73 d after dose 2) vaccine vs. 2 placebo</p>

Trial name; Author (year); Country (number of sites); Dates of enrolment Funding	Eligibility, Randomization & Blinding	Study Arms		Baseline Demographics	Outcome(s); Safety Assessment	Analysis	Results
		Vaccine arm	Placebo arm				
	<p>Randomized 1:1, stratified by age (≥18 to <65 y vs. ≥65 y) and being at risk for severe Covid-19 based on pre-existing risk factors as per CDC; centralized interactive response technology system</p> <p>Study personnel and participants were blinded, but pharmacists and vaccine administrators were unblinded; participants informed of group assignment at end of blinded phase and offered vaccine.</p>			<p>Positive: 680 (2.2%), similar between arms; Missing: 523 (1.7%), similar between arms</p>	<p>AEs leading to discontinuation from a dose and/or study withdrawal, MAAEs and SAEs, throughout study period (1-759 d)</p> <p>MedDRA classification for all solicited adverse reactions and unsolicited AEs</p> <p>Unblinded safety data reviewed by independent data and safety monitoring board</p>		
<p>C4591001 Trial, Phase 3 -adolescent cohort</p> <p>Frenck (2021)</p> <p>Oct 15, 2020 – Jan 12, 2021</p> <p>Argentina (NR), Brazil (NR), Germany (NR), South Africa (NR), Turkey (NR), USA (29)</p> <p>Industry-funded</p>	<p>Included adolescents 12-15 y and adults 16-25 y who were healthy or with stable pre-existing conditions</p> <p>Exclusions: medical history of SARS-CoV-2 infection or Covid-19 diagnosis; treatment with immunosuppressive therapy; diagnosed with immunocompromising condition</p> <p>Randomized 1:1; web-based system</p> <p>Study personnel evaluating safety</p>	<p>BNT 162b2 (Pfizer-BioNTech) 2 doses 21 d apart 30 mcg per 0.3 ml dose</p> <p>Randomized:</p> <p>12-15 y: 1,134 Dose 1: 1,131 Dose 2: 1,124</p> <p>16-25 y: 1,875 Dose 1: 1,869 Dose 2: 1,826</p> <p>Withdrawals:</p> <p>12-15 y After dose 1: 7 After dose 2: 0</p> <p>16-25 y After dose 1: 43 After dose 2: 20</p>	<p>Saline placebo 2 doses 21 d apart 0.3 ml per dose</p> <p>Randomized:</p> <p>12-15 y: 1,130 Dose 1: 1,129 Dose 2: 1,117</p> <p>16-25 y: 1,913 Dose 1: 1,906 Dose 2: 1,836</p> <p>Withdrawals:</p> <p>12-15 y After dose 1: 12 After dose 2: 1</p> <p>16-25 y</p>	<p>Total randomized: 12-15 y: 2,264 16-25 y: 3,788</p> <p>Total safety population: 12-15 y: 2,260 16-25 y: 1,098 (subset with e-diary data)</p> <p>Male 51% White 86%</p> <p>Baseline SARS-CoV-2: Positive: 12-15 y: 93 (4.1%), similar between arms 16-25 y: 64 (5.8%), similar between arms</p>	<p>Solicited local and systemic AEs during 7 d following each injection; Unsolicited AEs for 1 mo after dose 1 and SAEs for 6 mos after dose 2.</p> <p>MedDRA v23.1 classification.</p> <p>Unblinded safety data reviewed by independent data and safety monitoring board; ongoing for 2 y after dose 2.</p>	<p>12-15 y: Safety analysis included all participants who received at least one injection.</p> <p>16-25 y: subset of participants who received an e-diary to record reactogenicity events</p>	<p>Myocarditis/pericarditis: 0</p>

Trial name; Author (year); Country (number of sites); Dates of enrolment Funding	Eligibility, Randomization & Blinding	Study Arms		Baseline Demographics	Outcome(s); Safety Assessment	Analysis	Results
		Vaccine arm	Placebo arm				
	were blinded to group assignments		After dose 1: 70 After dose 2: 22				
C4591001 Trial, Phase 2/3 Polack(2021, primary publication) & Thomas(2021) Jul 27, 2020 – October 29, 2020 Argentina (1), Brazil (2), Germany (6), South Africa (4), Turkey (9), USA (130) Industry-funded	Included participants ≥16 y, healthy or with stable pre-existing conditions Exclusions: medical history of SARS-CoV-2 infection or Covid-19 diagnosis; treatment with immunosuppressive therapy; diagnosed with immunocompromising condition Randomized 1:1; web-based system Study personnel evaluating safety were blinded to group assignments; unblinded follow-up started Dec 2020	BNT162b2 (Pfizer-BioNTech) 2 doses 21 d apart 30 mcg per 0.3 ml dose Randomized: 22,085 Dose 1: 22,030 Dose 2: 21,759 Safety population: 21,926 Withdrawals: After dose 1: 271 After dose 2: 167	Saline placebo 2 doses 21 d apart 0.3 ml dose Randomized: 22,080 Dose 1: 22,030 Dose 2: 21,650 Safety population: 21,921 Withdrawals: After dose 1: 380 After dose 2: 273	Total randomized: 44,165 Total safety population: 43,847 Male 50.9% Median age 51.0 y 16-55 y 59.4% >55 y 40.6% White 82.0% Congestive heart failure 0.5% Myocardial infarction 1.0% Any malignancy 3.6% Rheumatic disease 0.3% AIDS/HIV 0.5% Baseline SARS-CoV-2 status: Positive: 1,405 (3.2%), similar between arms Missing: 277 (0.6%), similar between arms	Solicited local and systemic AEs during 7 d after each injection; Unsolicited AEs and SAEs for 1 mo and 6 mos after dose 2, respectively. MedDRA v23.1 classification; Unblinded safety data reviewed by independent data and safety monitoring board; ongoing for 2 y after second dose.	Safety analysis included all participants who received at least one injection irrespective of follow-up time.	Myocarditis: 0
ENSEMBLE Trial, Phase 3 Sadoff (2021) Sep 21, 2020 – Jan 22, 2021 Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, USA Industry-funded	Adults ≥18 y, healthy or with stable pre-existing conditions; excluded those who received chronic/recurrent systemic corticosteroids, or antineoplastic and immunomodulating agents or radiotherapy in prior 6 mo before study vaccine and during study, or are pregnant Randomized 1:1, stratified by site, age, and being at risk for severe Covid-19	Ad26.COVID.S (Janssen) 1 dose 5×10 ¹⁰ vp per 0.5 ml dose Randomized: 21,895 Safety population: 21,895 Withdrawals: 49	Saline placebo 1 dose x 0.5ml Randomized: 21,888 Safety population: 21,888 Withdrawals: 96	Total randomized: 44,325 Total safety population: 43,783 Male 54.9% Median age 52 y White 58.7% Serious heart condition 2.3% Immunocompromised from blood transplant, immune deficiencies, use of corticosteroids or other immunosuppressing medicines 0.2% Immunocompromised from organ transplant <0.1% Baseline SARS-CoV-2 status:	Solicited local and systemic AEs 7 d after injection (for subset of 6,000 participants); Unsolicited SAEs up to 28 d after injection, MAAEs until 6 mos after vaccination, and MAAEs leading to study withdrawal Independent data and safety monitoring board reviewed unblinded safety data.	Safety analysis included all participants who received injection	Pericarditis: 1 (<0.1%) vaccine vs. 0 placebo

Trial name; Author (year); Country (number of sites); Dates of enrolment Funding	Eligibility, Randomization & Blinding	Study Arms		Baseline Demographics	Outcome(s); Safety Assessment	Analysis	Results
		Vaccine arm	Placebo arm				
	based on pre-existing risk factors; interactive web response system Participants and study personnel (including HCW administering vaccine) blinded until either discontinuation or an event			Positive: 4,217 (9.6%), similar between arms Missing: 1,271 (2.9%), similar between arms			
AZD1222 Trial, Phase 3 Falsey (2021) Aug 28, 2020 – Jan 15, 2021 Chile, Peru, USA (88 total) Industry-funded	Included adults ≥18 y, with stable pre-existing conditions, at high risk for exposure to SARS-CoV-2 and at increased risk for severe Covid-19 Exclusions: history of SARS-CoV-2 infection; confirmed or suspected immunodeficiency, or with significant disease; pregnant or breastfeeding Randomized 2:1, stratified by age; method NR Group assignment unblinded for 7,635 (35.3%) AstraZeneca and 4,157 (38.4%) placebo participants, after the second dose.	AZD1222 (AstraZeneca) 2 doses 4 wks apart 5 x 10 ¹⁰ vp per dose Randomized: 21,635 Dose 1: 21,583 Dose 2: 20,769 Safety population: 21,587 Withdrawals: After dose 1: 283 After dose 2: 228	Saline placebo 2 doses 4 wks apart Randomized: 10,816 Dose 1: 10,769 Dose 2: 9951 Safety population: 10,792 Withdrawals: After dose 1: 240 After dose 2: 258	Total randomized: 32,451 Total safety population: 32,379 Male 55.6% Mean age: 50.2y ≥18-64 y 77.6% ≥65 y 22.4% White 79.0% Serious heart condition 3.3% Cancer 6.5% Immunocompromised due to solid organ transplantation <0.1% HIV infection 1.6% Baseline SARS-CoV-2 status: Positive: 915 (2.8%), similar between arms Missing/not performed: 575 (1.8%), similar between arms	Solicited local and systemic AEs 7 d after each injection; Unsolicited AEs up to 28 d after injection, SAEs, MAAEs, and MEs of special interest up to 730 d after informed consent	Safety analysis included all participants who received at least one injection.	Myocarditis/pericarditis: 0
AZD1222 Phase 1/2/3, pooled analysis Voysey (2021a; primary publication) & Voysey (2021b) Apr 23, 2020 – Dec 6, 2020	Adults ≥18 y, healthy or with stable pre-existing conditions, or at risk of exposure (health and social care setting workers, 58.5%)	AZD1222 (AstraZeneca) 2 doses 4-12 wks apart 2.2-6.5x10 ¹⁰ vp per 0.5ml dose, 2 Randomized: 12,408	Meningococcal ACWY vaccine (UK) OR Meningococcal ACWY vaccine (dose 1) + saline placebo (dose 2; Brazil) OR	Total randomized: 24,422 Total safety population: 24,244 Male 44% Median age NR 18-55 y 82.5%	Solicited local and systemic AEs for 7 d after each injection observed by investigator or reported by participant;	Safety analysis included all participants who received at least one injection.	Pericarditis: 1 vaccine (0 grade 3 severity) vs. 2 (1 grade 3 severity) controls

Trial name; Author (year); Country (number of sites); Dates of enrolment Funding	Eligibility, Randomization & Blinding	Study Arms		Baseline Demographics	Outcome(s); Safety Assessment	Analysis	Results
		Vaccine arm	Placebo arm				
Brazil (6), South Africa (8), UK (5+19) Industry-funded	Exclusions: confirmed or suspected immunosuppressive or immunodeficiency state; current diagnosis of cancer; pregnant or breastfeeding Randomized 1:1, stratified by study site and study group; secure web platform Single blind (Brazil, UK); double blind (South Africa) - study personnel and participants blinded, but pharmacist preparing vaccines unblinded	Safety population: 12,282 (after exclusion of 52 participants in HIV cohort) Withdrawals NR	Saline placebo (South Africa) For all: 2 doses 4-12 wks apart 0.5 ml dose Randomized: 12014 Safety population: 11,962 (after exclusion of 52 participants in HIV cohort) Withdrawals NR	56-69 y 11.3% 70+ y 6.1% White 75.2% Cardiovascular disorder (includes cardiac diseases) 12.3% Baseline SARS-CoV-2 status: Positive: 731 (3.0%), similar between arms Missing: 200 (0.8%), similar between arms Sensitivity analyses for participants positive for SARS-CoV-2 at baseline and using ITT were similar to main results	Unsolicited AEs through to 28 d after each injection, and SAEs and AEs of special interest throughout study period from last dose to 364 d. MedDRA v23.1 classification, severity classified according to FDA toxicity rating scales. Independent data monitoring safety board reviewed safety data on an ongoing basis		

AE: adverse event(s); LTFU: lost to follow-up; MAAE: medically-attended adverse event(s); mcg: microgram(s); mo: month(s); no.: number; NR: not reported; SAE: serious adverse event(s); vp: viral particle(s); wks: weeks; y: year(s)

Table A5. Risk of bias assessments for randomized controlled trials (question 1)

Vaccine (Trial name)	Randomization	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall assessment of risk of bias
Moderna (Teen COVE Trial) Ali 2021	Low	Low	Some concerns	Low	Low	Some concerns
Moderna (COVE Trial) Baden 2021 & El-Sahly 2021	Low	Low	Low	Low	Low	Low
Pfizer-BioNTech (Teen C4591001 Trial) Frenck 2021	Low	Low	Low	Some concerns	Low	Some concerns
Pfizer-BioNTech (C4591001 Trial) Polack 2021 & Thomas 2021	Low	Low	Low	Some concerns	Low	Some concerns
AstraZeneca (AZD1222 Trial) Falsey 2021	Low	Some concerns	Some concerns	Low	Low	Some concerns
AstraZeneca (Oxford Vaccine Trial) Voysey 2021a & 2021b	Low	Some concerns	Some concerns	Low	Low	Some concerns
Janssen (ENSEMBLE Trial) Sadoff 2021	Low	Low	Low	Low	Low	Low

Appendix 4. Summary of Findings from the Randomized Controlled Trials (question 1)

Age category	Age, risk status	Country (number of sites)	Vaccine (risk interval)	Number of participants in safety analysis	Number of participants with outcome	Conclusion	GRADE
	Myocarditis						
12-17 y	12-17 y	USA (26) Ali	Moderna (28 d)	3,726	0	RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of Moderna in youth 12-17 years of age.	Very low ^a
Adolescents and young adults	12-25 y	USA (29) Frenck	Pfizer (21 d)	3,357	0 (assumed, NR)	RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of Pfizer in adolescents and young adults.	Very low ^a
Adolescents and adults	≥16 y	Argentina (1), Brazil (2), Germany (6), South Africa (4), Turkey (9), USA (130) Polack/Thomas	Pfizer (21 d)	43,847	0	RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of Pfizer in adolescents and adults.	Very low ^b
Adults	≥18 y, at risk of exposure to SARS-CoV-2 and/or increased risk for severe Covid-19	USA (99) Baden/E-Sahly	Moderna (28 d)	30,351	0	RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of currently available vaccine by adults	Very low ^b
	≥18 y, at high-risk of exposure to SARS-CoV-2 and increased risk for severe Covid-19	Chile, Peru, USA (88 altogether) Falsey	AstraZeneca (28 d)	32,379	0 (assumed, NR)		
	≥18 y, 59% at risk of exposure to SARS-CoV-2	Brazil (6), South Africa (8), UK (24) Voysey	AstraZeneca (4-12 wk)	24,244	0 (assumed, NR)		
	≥18 y	Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, USA (number of sites NR) Sadoff	Janssen (single dose)	43,783	0 (assumed, NR)		
	Pericarditis						

Age category	Age, risk status	Country (number of sites)	Vaccine (risk interval)	Number of participants in safety analysis	Number of participants with outcome	Conclusion	GRADE
12-17 y	12-17 y	USA (26) Ali	Moderna (28 d)	3,726	0	RCTs provided very uncertain evidence about the incidence of pericarditis after receipt of Moderna in youth 12-17 years of age.	Very low ^a
Adolescents and young adults	12-25 y	USA (29) Frenck	Pfizer (21 d)	3,357	0 (assumed, NR)	RCTs provided very uncertain evidence about the incidence of pericarditis after receipt of Pfizer in adolescents and young adults.	Very low ^a
Adolescents and adults	≥16 y	Argentina (1), Brazil (2), Germany (6), South Africa (4), Turkey (9), USA (130) Polack/Thomas	Pfizer (21 d)	43,847	0 (assumed, NR)	RCTs provided very uncertain evidence about the incidence of pericarditis after receipt of Pfizer in adolescents and adults.	Very low ^b
Adults	≥18 y, at risk of exposure to SARS-CoV-2 and/or increased risk for severe Covid-19	USA (99) Baden/E-Sahly	Moderna (28 d)	30,351	2 (68 d & 73 d post-second dose) vs. 2 placebo	RCTs provided very uncertain evidence about the incidence of pericarditis after receipt of currently available vaccine by adults	Very low ^b
	≥18 y, at high-risk of exposure to SARS-CoV-2 and increased risk for severe Covid-19	Chile, Peru, USA (88 altogether) Falsey	AstraZeneca (28 d)	32,379	0 (assumed, NR)		
	≥18 y, 59% at risk of exposure to SARS-CoV-2	Brazil (6), South Africa (8), UK (24) Voysey	AstraZeneca (4-12 wk)	24,244	1 vs. 2 controls		
	≥18 y	Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, USA (number of sites NR) Sadoff	Janssen (single dose)	43,783	1 (<0.1%) vs. 0 placebo		

GRADE Explanations:

^a Rated down for indirectness since results by sex are expected to differ; rated down twice for high imprecision for these very rare events.

^b Rated down twice for indirectness and for imprecision for these very rare events.